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CHANGES IN INTRAOCULAR PRESSURE 
FOLLOWING  SUCCINYLCHOLINE 
ADMINISTRATION AND ENDOTRACHEAL 
INTUBATION-INFLUENCE OF DEXMEDETOMIDINE 
PREMEDICATION 
 
 
ABSTRACT 
Background:  Use of succihylcholine in a penetrating eye injuries can cause a 
dreaded complication of vision damage because it causes dangerous increase in 
intraocular pressure and thus causes globe rupture. So the purpose of the study 
was to observe the efficacy of intravenous dexmedetomidine premedication in 
preventing the rise in intraocular pressure following succinylcholine and 
intubation. 
Methods: 60 ASA 1or 2 patients undergoing elective non ophthalmic surgeries 
were included in this prospective randomized study. Patients were allocated into 
three groups  to receive 0.4microgrms/kg ,0.6 micrograms/kg,and normal saline 
to groupD4,D6 and Control group respectively 10 minutes before induction as 
intravenous premedication over 10 minutes. Intraocular pressure was observed 
before  and after premedication ,after thiopentone administration ,after 
succinylcholine administration and at 1minute and 5 minute after intubation. 
Pulse rate, systolic blood pressure ,diastolic blood pressure and SPO2 monitored 
at the same time points and at various intervals througout the surgery. 
Results: Fall in intraocular pressure was observed after premedication in the 
study group. IOP increased in all three groups after succinylcholine and 
intubation but it never crossed the baseline in study groups where as 
significantly elevated above the baseline in control group. Both doses 
effectively blunted the sympathetic response to laryngoscopy and intubation but 
a better hemodynamic stability was observed with the dose 0.4 μg/kg. 
Conclusion: Dexmedetomidine both doses are equally effective in preventing 
the rise in IOP and blunting the sympathetic response but a better hemodynamic 
stability is observed with the dose 0.4 μg/kg. Hence dexmedetomidine 0.4μg/kg 
may be used for preventing the rise in intraocular pressure. 
Keywords: Dexmedetomidine, Intraocular pressure, succinylcholine, 
premedication, endotracheal intubation. 
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INTRODUCTION 
 
   One of the most important preequisite of any anaesthetic 
procedure is a good perioperative hemodynamic stability during laryngoscopy 
and intubation. The potential for complications due to hemdynamic and 
intraocular pressure response to laryngoscopy and intubation is well studied and 
reported. A wide array of techniques have been proposed regarding the 
protective measures against the sympathetic response, intraocular pressure 
response and  catecholamine response of laryngoscopy and intubation. 
   An increase in intraocular pressure associated with any 
anaesthetic procedure or drug may or may not have a significant effect on a 
healthy individual. But the same situation in a patient with an already elevated 
intra ocular pressure will be an entirely different context. Thus the drugs or 
techniques for optimization of intraocular pressure is highly desirable in cases 
like penetrating eye injury. 
  Different  methods have been tried to blunt the intraocular pressure 
increasing effect of succinylcholine. ‘Self taming’ where a small amount of the 
drug is given first followed by the remaining amount of the drug is one of the 
options. Pre treatments with various agents like nondepolarizing muscle 
relaxants, lignocaine, nifedipine nitroglycerine etc.. are some of the other 
methods. Every modality has its own advantages and disadvantages and none of 
the methods are completely devoid of drawbacks. 
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   Emergency ophthalmic surgeries is most often a challenging  
experience for an anaesthesiologist especially in situations like penetrating 
globe injuries. As most of these patients present with full stomach they are at a 
high risk for aspiration. In case of an open globe injury, any factor that increases 
the intraocular pressure may cause aqueous humour drainage or extrusion of the 
vitreous humour through the wound and may lead to permanent damage to 
vision. 
   Hence these patients require rapid sequence induction to 
prevent aspiration and at the same time the dangerous increase in intraocular 
pressure should also be prevented. Succinylcholine is the depolarizing muscle 
relaxant  commonly used to facilitate rapid sequence induction. But one of the 
most common side effects of succinylcholine is that it increases the intra ocular 
pressure. The stress response during laryngoscopy and endotracheal intubation 
also further aggravates the intra ocular pressure. 
   Alpha 2 agonists have a favourable use in ophthalmic 
surgeries because of its  lowering effect on intraocular pressure and  
sympathetic response attenuation effect. Alpha 2 agonists like clonidine and 
dexmedetomidine,both have the above mentioned  properties. Both clonidine 
and dexmedetomidine act on both alpha 1 and alpha 2 receptors but 
dexmedetomidine is  highly selective and specific for  alpha-2 adrenergic 
receptor. Some of the other well documented effects of dexmedetomidine are 
sedation, anxiolysis, sympatholysis and analgesia with minimal respiratory  
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depression.The elimination half life of dexmedetomidine is   2-3 hours. 
   Dexmedetomidine is being used in other countries since 
many years ; and in India it is recently introduced.The anaesthetic goal of any 
ophthalmic surgery is to provide a good control of intra ocular pressure, an 
immobile and uncongestive operative field and good cardiovascular stability. 
Hence this study was conducted to determine the effect of two doses of 
dexmedetomidine premedication on  intra ocular pressure after succiylcholine 
administration and intubation. 
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AIM AND OBJECTIVES OF THE STUDY 
    
   To study the efficacy of two doses of intravenous 
dexmedetomidine  premedication  given as a  single bolus dose over 10 minutes, 
0.4 micrograms/kg and 0.6 micrograms /kg ,10 minutes before induction  in 
preventing the rise of intra ocular pressure following succinylcholine 
administration and endotracheal intubation. 
PRIMARY OBJECTIVE: 
  To study the effect of dexmedetomidine premedication on intra 
ocular pressure following succinylcholine administration, and intubation. 
SECONDARY OBJECTIVES: 
1) To study the  intraocular pressure changes following 
succinylcholine and intubation. 
2) To study the effect of dexmedetomidine on attenuation of 
sympathetic response during laryngoscopy and intubation 
3) To study any adverse effect associated with dexmedetomidine 
administration 
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HISTORY 
   In 1906 Succinylcholine was first described by Reid Hunt 
& Rene de M Taveau. But when studying the effect of the drug on  animals , 
they were given Curare. So they missed the neuro muscular blocking properties 
of the drug and hence did not get attention for the discovery.  
   In 1949- an Italian group led by a scientist Daniel Bovet was 
the first to describe succinyl choline induced paralysis. He studied the chemical 
and physiological properties of succinylcholine for which he received Nobel 
prize for physiology and medicine in 1957. In the same year Buttle and Zaimis 
published a paper on the pharmacological properties of succinyl choline.  
   In 1950 after  Walker published  the first paper on succinyl 
choline synthesis it widely came into use in  clinical practice.  
   In 1955 Lincoff  first noted a tremendous increase in intra 
ocular pressure following succinyl choline administration for an open eye injury 
case. 
   Dexmedetomidine was developed by Abott laboratories in 
the year 1990. The drug was initially developed for intensive care unit as a 
sedative. It was in 1999 Abott received the approval from F.D.A for marketting 
the drug.  
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HISTORY OF INTRA OCULAR PRESSURE MEASUREMENT 
    
  In 1863-Von Graffe deviced an instrument to measure the intra  
ocular pressure through eyelid or sclera. But topical anaesthesia was not  
available at that time. He used a weight loaded plunger for indenting the cornea 
and measured the intraocular pressure. 
   It was in 1884 Karl Koller studied the local anaesthetic 
properties of Cocaine after which cocaine came into use for  topical ophthalmic 
anaesthesia . This paved a foundation for the development of  new ways of 
measuring intra ocular pressure. 
   Imbert (1885) and Fick (1888) developed a physical 
principle  on which all  applanation tonometers are based. The basis of the 
principle was that in a sphere the pressure inside can be calculated as the force 
in grams required to applanate a given area in millimeter square. Fick himself 
developed a simple tonometer based on his principles.  
   Russian Alexei Maklakoff in 1885 developed the first 
practical tonometer for office use in the hospital Moscow Eye Hospital. 
   Goldmann developed the first fixed area applanation 
tonometer based on Imbert – Fick principles. The applanating suface was of an 
area 3.06mm. This was kept in the center of a plastic cylinder and the whole 
apparatus was mounted on a slit- lamp microscope.  
   The first reasonably accurate  indentation tonometer was  
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developed by Hjalmer Schiotz in 1905,a Norwegian physician. It was  based  
on the principle that the indentation of a force or weight into a softer object is 
more than that into a harder object. The simple easily portable instrument is the 
only indentation tonometer which is used widely in practice. Schiotz’s concept 
of ocular rigidity was bsed on the Hooks Law. In 1923 Balliart deviced a new 
type of indentation tonometer. In 1958 Maurice developed electrical method of 
reading  of the indentation tonometer. 
   In 1959 McKay and Marg introduced tonometers based on 
a combination of indentation and applanation tonometers. 
   A handheld applanation tonometer the Perkins tonometer 
was developed in the year 1965. 
   The newest development based on the concept of rebound 
tonometry was described in Icare, Helsinki, Finland. 
   In 2005  totally new concept in tonometry , ‘Dynamic 
Contour Tonometry ’ was  developed by Kangeisser et al. 
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PHYSIOLOGY OF INTRAOCULAR PRESSURE 
    The  tissue pressure of intraocular contents is called the 
INTRA OCULAR PRESSURE. Normal  intraocular pressure is 16 ± 4 mm Hg. 
The intraocular pressure in general population usually varies between 10-20 mm 
Hg. Values above 21 mmHg is considered to be pathological. The importance of 
maintaining a normal intraocular pressure is to maintain an optimal corneal 
curvature and refraction and thus proper vision. 
    An understanding of the physiology of a normal  intraocular 
pressure and the alterations in intra ocular pressure due to various factors is 
important to an anaesthesiologist due to various reasons.Patients with an open 
globe as in a penetrating eye injury may present with an already elevated IOP, 
and it is a situation where general anaesthesia must be instituted on an 
emergency basis as well as without further increase in intra ocular pressure. 
Also patients with an elevated intraocular pressure due to an acute or chronic 
eye disease may present for ophthalmic surgeries and it is clear that a 
continuous control of intraocular pressure is an important requirement in such 
intraocular surgeries.Patients with a chronically elevated intraocular pressure  
presenting for a non ophthalmic surgery can also occur. Moreover several 
procedures and drugs in anaesthesia can affect intraocular pressure significantly. 
Hence maintenance of a dynamic balance  between the factors elevating and 
reducing  the intraocular pressure is important to an anaesthesiologist. 
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DETERMINANTS OF INTRA OCULAR PRESSURE 
  The physiologic determinants of intra ocular pressure are 
1. Aqueous humour dynamics 
2. Choroidal blood volume 
3. Vitreous humour volume 
4. Extra ocular muscle tone and external compression 
 
AQUEOUS HUMOUR DYNAMICS 
   Aqueous humour is a clear fluid. Its Ph is 7.1-7.2, viscosity 
is 1.025-1.040 with a lesser protein , urea and glucose content than plasma. It 
occupies the anterior and posterior chambers of the eye. It constitute a total 
volume of 0.3 ml  of which 0.25 ml is in anterior chamber and 0.05 ml is in 
posterior chamber. 
    Aqueous humour is produced mainly by the ciliary bodies 
and its main function is supply of oxygen and glucose  to  avascular lens and 
cornea. There are mainly two mechanisms for the production of aqueous 
humour. The  major mechanism is via an active secretion (80 %) where Na+-K+ 
ATP ase enzyme creates an osmotic gradient for the passage of water into the 
posterior chamber. The other minor mechanism is through ultrafiltration(20 %).  
The blood pressure in the ciliary body,   intraocular pressure and plasma oncotic 
pressure influence the rate of ultra filtration.  
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Fig 1 : Aqueous humour dynamics
     
    The aqueous humour thus produced flows from the poste
chamber into the anterior chamber and from there it is removed by two 
mechanisms. 
1. Major resorption occurs through the trabecular network and Canal of 
Schlemm in the angle  between iris and cornea.
with the episcleral veins and 
between episcleral venous pressure and intra ocular pressure.
 
 
 This canal communicates 
and this absorption depends on a gradient 
 
 
rior 
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2. Nearly 20 % of the absorption occurs through uveoscleral route . 
  The aqueous from the episcleral veins thereafter drain into orbital  
venous system and finally  reaches  cavernous sinus  through  superior and  
inferior ophthalmic veins. 
 
CHOROIDAL BLOOD VOLUME 
   Any change in the blood volume of the eyeball will cause a 
change in intra ocular pressure. The choroid is highly vascular with extensive 
anastomoses between the anterior ciliary arteries and long and short  posterior 
ciliary arteries. The choriocapillaries have the property of autoregulation and 
thus the choroidal blood volume is maintained constant through a range of 
perfusion pressures. A sudden rise of systolic blood pressure increases the 
intraocular pressure. This  temporarily increases  the outflow which in turn  
brings the intraocular pressure to normal . Moderate reduction in arterial 
presssure does not have much significance on intraocular pressure, but  mean 
arterial  pressure below 90 mmHg  cause a decrease in intra ocular pressure. 
   The choroidal blood volume is sensitive to changes in partial  
pressure of carbon dioxide .Any increase in partial pressure of carbon dioxide 
or respiratory acidosis  will increase the choroidal blood volume, increase the 
aquoeus humour production and decrease the aquoeus outflow thereby leading 
to elevation of intra ocular pressure. Respiratory alkalosis decreases the 
choroidal blood volume, reduce blood flow to the ciliary process and decrease  
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the ultra filtration of aqueous humour and thus reduces intra ocular pressure. 
   Metabolic acid base abnormalities have an opposite effect on 
intraocular pressure compared to respiratory acid – base changes. Metabolic 
acidosis reduces the intra ocular pressure and metabolic alkalosis increases the 
intraocular pressure. 
   The choroidal circulation  is also affected by changes in 
partial pressure of oxygen. Hyperbaric oxygen tension leads to vaso 
constriction of choroidal blood vessels and thereby reducing the intra ocular 
pressure. Hypoxaemia  causes vasodialation and increases the intraocular 
pressure. 
   An increase in the central venous pressure caused by an 
obstruction to venous return or by coughing , valsalva manuevre or straining at 
endo tracheal tube   can lead to a  sharp and immediate elevation of  intra 
ocular pressure. Coughing can increase the intra ocular pressure to 30 – 40 mm 
Hg. A slight head up tilt may help during intra ocular surgeries by reducing the 
intra ocular pressure. 
VITREOUS HUMOUR VOLUME 
   The vitreous is an unstable gel with fine fibrillary substance 
and water. By dehydrating the vitreous the volume , the pressure effect of the 
vitreous may be reduced.  Oral glycerol 2g/kg , intravenous mannitol infusion  
1.5 mg /kg, or urea 30 % solution in water are all methods to reduce the intra 
ocular pressure. 
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EXTRA OCULAR MUSCLE TONE AND EXTERNAL COMPRESSION 
   Extra ocular muscles are under the direct neurogenic control 
of  midbrain. The intra ocular pressure is altered by the tone of extra ocular 
muscles. When a patient becomes completely under general anaesthesia central 
nervous system depression of these control centers occurs which reduces the 
tone of extra ocular muscles and hence in turn reduces intra ocular pressure . 
   Contraction of orbicularis oculi muscle , eyelid closure or 
the contraction of  other extrinsic muscles of the eyeball causes  increase in the 
intra ocular  pressure.  A  normal blink  may  increase the  intra  ocular    
pressure   to 10 mm Hg. An increase  of  intraocular pressure to almost 50 mm 
Hg may be caused by a sudden forceful squeeze of the eyeball. Sudden 
compression of the eyeball  as can occur with an incorrect placement of 
facemask may also lead to increase of intra ocular pressure. 
 
TABLE 1.  SUMMARY OF PHYSIOLOGICAL DETERMINANTS OF 
    INTRAOCULAR PRESSURE 
Aqueous humour dynamics 
1.production 
2. drainage 
 
Choroidal blood volume 
1.auto regulation 
2.central venous pressure 
3.Partial pressure of carbondioxide 
4.partial pressure of oxygen 
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5. metabolic – pH 
 
Vitreous humour 
1.osmotic pressure 
 
Extra ocular muscle tone  
1.neurogenic control 
 
 
FACTORS AFFECTING THE INTRA OCULAR PRESSURE 
1.Sex of the patient 
    Upto middle age of around 40 years there is no variation in 
intraocular pressure between the two sexes . In older age group the mean intra 
ocular pressure is 1 mm Hg higher in females than in males. 
2.Age of the patient 
   The mean intraocular pressure in newborn is15- 29mm Hg.  
This may be because of the high rate of aqueous humour production in them. 
Thereafter the intraocular pressure falls steadily and becomes the normal value. 
In children aged around 8-10 years, the mean intraocular   pressure is usually    
15mm Hg. 
3.Postural  variation 
   The intraocular pressure varies with different positions. 
From sitting to supine position it increases by 0.3 – 6 mm Hg. It increases 
further on head down position.  Increased  episcleral venous pressure is the 
cause for this change. 
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4.Diurnal variation 
   Normal intraocular pressure has a diurnal variation. A higher 
value is seen  in the morning, lower value seen  in the afternoon and evening. 
The  normal variation is around 2-3 mm Hg. Circadian adrenocortical hormone 
secretion, immobile eye, supine position , pupillary dialation during sleep and 
carbon dioxide retention may all be contributing factors for the increased value  
seen in morning. 
EFFECT OF ANAESTHESIA AND ADJUVANT DRUGS ON 
INTRA OCULAR PRESSURE 
   Opthalmological surgeries comprises of extra ocular 
surgeries and intra ocular surgeries. Intraocular pressure does not have a much 
significant impact on extra ocular surgeries. But intra ocular pressure does have 
a significant role on intraocular surgeries like intra capsular lens extraction, 
surgeries for penetrating eye injuries  drainage surgeries for glaucoma etc... 
These are indeed some of the situations important for an anaesthesiologist 
,since only a good control of intra ocular pressure can produce a successful 
outcome. A sudden rise in intra ocular pressure in these circumstances may 
lead to lens prolapse, vitreous loss or choroidal haemorrhage which inturn can 
lead to permanent damage of vision. 
   Drugs administered during anaesthesia may affect 
intraocular pressure in different ways.It may be through direct action on control 
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centers in the central nervous system. Other mechanisms by which anaethetic 
drugs affect the  intraocular pressure are through inhibition or facilitation of 
aqueous humour production or drainage or through contraction or relaxation of 
extra ocular muscles. An Indirect mechanism proposed is through the drug’s 
effect on cardio vascular and respiratory mechanics. 
PREMEDICANTS 
   Anti cholinergics like atropine, glycopyrrolate , or 
scopolamine when administered intra muscularly does not have a significant 
effect on intra ocular pressure. But anticholinergics  when  topically 
administered to eye causes mydriasis and increase the intra ocular pressure.  
Atropine when given in the usual premedication dose, does not cause mydriasis 
and increase of intra ocular pressure. 
   Commonly used anxiolytics like benzodizepines lower the 
intra ocular pressure. Orally administered diazepam does not lower the 
intraocular pressure where as intravenous diazepam decrease the intra ocular 
pressure. When intra venous diazepam is administered as a premedicant five 
minutes before induction , though it lowers the intraocular pressure initially ,  
following succinylcholine administration and intubation the intraocular 
pressure rises and the value goes above the baseline. Hence using diazepam to  
attenuate the rise of intraocular pressure following succinylcholine may not 
produce an actually promising effect.  Comparison of midazolam  with 
diazepam was studied by Fragen and Hausch. The results were that midazolam 
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produced a reduction of intraocular pressure in a similar manner and in a same 
degree as that of diazepam. 
LARYNGOSCOPY AND INTUBATION 
   Intraocular pressure is increased by laryngoscopy and 
intubation. Sympathetic stimulation accompanying laryngoscopy and 
intubation is the main reason for this. Adreneric stimulation causes 
vasoconstriction and increased central venous pressure both of which it is  
closely associated with  elevation of intraocular pressure. In addition 
sympathetic surge may also cause a decrease in outflow of aqueous humour by 
increasing the  resistance in the trabecular mesh work between anterior 
chamber and canal of Schlemm. This in turn cause an acute increase in 
intraocular pressure. Thus there is a close relationship between hemodynamic 
response and intra ocular pressure. This explains the role of pretreatment for 
stress attenuation during laryngoscopy and intubation which may help to blunt 
the rise of intra ocular pressure. The pre -treatments including intra venous 
lignocaine  (1.5 mg/kg)  3-5 minutes before induction, orally administered 
centrally acting drug clonidine 2 hours before induction, intra nasal 
nitroglycerine etc.. are some of the successful methods tried and proved for 
reducing the sympathetic response. 
GENERAL ANAESTHETIC AGENTS 
INTRA VENOUS ANAESTHETICS  
   In general most of the central nervous system depressants  
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reduce the intra ocular pressure. Sleeping dose of thiopentone and propofol 
both decrease the intraocular pressure. Thiopentone reduces the 
intraocularpressure by about 40% and propofol by 50 %. Reduction of 
intraocular pressure occurs mainly by depressive effect on the diencephalon of 
brain (control centers of extra ocular muscles) and by increasing the outflow of 
aqueous humour. Etomidate though it produces pain and  myoclonus it is also 
associated with the reduction in intra ocular pressure. Ketamine is known to 
produce increase of IOP. Further the blepharospasm and nystagmus which it 
produces is also not suitable for ocular surgeries. Hence it is better avoided in 
ophthalmic surgeries. 
   Opioids in moderate doses when administered is associated 
with reduction in intra ocular pressure. Opioids like fentanyl , sufentanyl and 
alfentanyl can be used for reducing the pressor response and preventing the rise 
of intra ocular pressure during laryngoscopy and intubation. 
INHALATIONAL AGENTS 
   The earliest studies on the effect of inhalational anaesthetics 
on intra ocular pressure reported a dose dependent decrease in intraocular 
pressure when diethyl ether , cyclopropane or vinyl ether were used. 
Subsequent studies proved trichloroethylene, halothane and chloroform also 
produced similar and comparable reduction in intra ocular pressure. 
   The degree of intra ocular pressure reduction associated with 
inhalational agents closely corelates with the depth of anaesthesia, extent of   
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relaxation of smooth muscle tone   and degree of reduction in blood pressure. 
   When a 0.5 % halothane was used along with nitrous oxide 
and  oxygen it produced a 50 % reduction of intraocular pressure. Reduction of 
intraocular pressure was lesser when trichloroethylene was used when 
compared to halothane. A comparison between equi MAC concentrations of 
halothane and enflurane showed 14 % reduction in intraocular pressure  with 
halothane and 40 % reduction of IOP with enflurane. Isoflurane also 
significantly reduces intraocular pressure. Desflurane also has a similar profile 
as that of isoflurane with respect to intraocular pressure changes. Sevoflurane 
is also found to decrease the intraocular pressure and maintains the intraocular 
pressure values in a lower range throughout surgery. 
 
NEUROMUSCULAR BLOCKING DRUGS 
SUCCINYLCHOLINE 
   The earliest report that succinyl choline produced a 
tremendous increase in intra ocular pressure when used in open globe injuries 
was given by Lincoff in 1955. Since then many authors have studied and 
reported about this subject of intra ocular pressure and succinylcholine. 
   Following induction with thiopentone and succinyl choline 
the intra ocular pressure rises within the first minute itself. It then attains the 
peak rise of 6-8 mmHg in next 2-4 seconds and remains elevated upto around 6 
minutes. After intubation the rise of intra ocular pressure is aggravated but not  
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prolonged. 
Mechanism of  increase in intraocular pressure  following succinylcholine 
administration 
   The main mechanism of rise in intra ocular pressure 
following succinyl choline is due to the  contraction of extra ocular muscles. 
The unique histology of extra ocular muscles and hence the different 
physiological response of these muscles to the  neuro muscular blocking drugs 
plays an important role with respect to anaesthesia.  All the adult human 
muscle cells in a unit are innervated by a single neuron. Thus electrical 
stimulation of the nerve, or an action potential from ventral horn or any agonist 
like depolarizing muscle relaxant causes all the muscle cells to contract 
synchronously. This synchronous contraction is called fasciculation.  But extra 
ocular muscles are an exception to this and they are “tonic” muscles. They are 
innervated by multiple neurons with several neuro muscular junctions along the 
surface of each muscle cell (Felderstruktur). Another contrasting feature is that 
mature and immature fetal receptors are present  even in adult muscle cells. 
The importance of these unique features are that , the extra ocular muscles 
respond to succinyl choline by a slow , steady and long lasting contraction 
unlike other skeletal muscles. The strength of the contraction is proportional to 
the stimulus received. This special contracture response pulls the eye against 
the orbit and thus contribute to an increase of intra ocular pressure. The other 
possible mechanisms for the rise in intraocular pressure include increase in 
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choroidal blood volume following choroidal vaso dialation or distortion of 
globe due to axial shortening.  
   Various studies have been done on the factors affecting the 
succinyl choline induced rise in intra ocular pressure. Joshi and Bruce found 
out that the timing of administration of succinylcholine and thiopentone is a 
factor on which the changes in IOP associated with succinylcholine 
administration depends. A 1 mg/kg dose of succinylcholine  given immediately  
after thiopentone dose of 3 mg/kg produced a decrease in intraocular pressure 
and when the same dose of succinyl choline given 3 min after thiopentone 
produced an increase in intra ocular pressure above the baseline.  Cook found 
no dose response effect with succinyl choline as he reported that the rise in 
Intra ocular pressure was same after 1 mg/kg of succinylcholine and 2.5mg/kg 
succinyl choline following thiopentone 3 mg/kg. 
   Many techniques have been advocated in various studies to 
attenuate the rise of intraocular pressure induced by succinyl choline. Miller 
reported that dTc and gallamine pretreatments can attenuate  the increase of 
intraocular pressure  produced by succinyl choline. A small self taming dose of  
10 mg before giving the full intubating dose can prevent the increase in 
intraocular pressure was reported by Verma et al. Cunningham et al described a 
0.1mg/kg pretreatment of  oral diazepam attenuated the rise of IOP. 
NON DEPOLARIZING MUSCLE RELAXANTS 
   The non depolarizing neuro muscular blocking drugs are  
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associated with a reduction in intra ocular pressure. The different mechanisms  
proposed are relaxation of extra ocular muscles, hypotension and ganglion 
blocking effects. In 1974 Albrak and Samuel studied  the effects of equipotent 
doses of pancuronium and dTc on intraocular pressure. They found out  that dtc 
produced significant reduction in intra ocular pressure and systemic  blood 
pressure while pancuronium did not have that significant effect. The 
intermediate acting drugs like vecuronium and atracurium are preferred drugs 
in ophthalmic surgeries and in situations where the intra ocular pressure is 
already high because these drugs will not produce a significant effect on 
intraocular pressure. 
   Rocuronium which has a very fast onset of action and which  
provides an excellent intubating conditions like succinyl choline can be an 
alternative option when the intraocular pressure is high because rocuronium 
produces a decrease in intraocular pressure. Hence a dose of 0.9- 1.2 mg /kg 
may be used in these situations. 
LOCAL ANAESTHETICS 
   The instillation of local anaesthetic into the orbit would be 
expected to cause an increase in intraocular pressure. Indeed a rise in 
intraocular pressure was reported after peri bulbar block. But sub tenon block 
usually produce a reduction of IOP , a probable cause may be the decrease in 
tone of extra ocular muscle. 
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ANAESTHESIA AND OPEN GLOBE 
   An understanding of the physiology and the factors affecting 
the  intraocular pressure underlines certain basic principles in anaesthetic 
management of an open globe injury. There are certain specific  anaesthetic 
goals to be followed  in a surgery of  penetrating eye injury . A preoperative 
acid aspiration prophylaxis should  be given before induction as most of these 
patients present with a full stomach.A smooth induction is always desirable to 
prevent  increase in intraocular pressure as much as possible associated with 
laryngoscopy and intubation. Use of depolarizing muscle relaxant must be  
based on risk assessment of both raised intraocular pressure and risk of 
aspiration.If a depolarizing muscle relaxant is to be used , methods for 
attenuating the rise of intraocular pressure may be adopted.Intubation with care 
to avoid coughing and sympathetic responses during laryngoscopy and 
intubation must be observed.Ventilation to maintain the partial pressure of 
oxygen and carbon dioxide in an optimum range should be adopted. Too much 
of head up tilt must be avoided as it may cause  obstruction of venous return. A 
smooth extubation as induction is always ideal.Post operative care to avoid 
nausea and vomiting must also be instituted. 
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MEASUREMENT OF INTRA OCULAR PRESSURE 
TECHNIQUES AND APPARATUS 
   Intra ocular pressure can be measured directly (manometry) 
or indirectly (tonometry). Manometric studies involve directly cannulating the 
anterior chamber or vitreous of the eye. It is then connected to a mercury or 
water manometer and  the  intraocular pressure is measured. It is used only in 
experimental studies in animal eyes ;cannot be used in human eyes. Indirect 
methods or tonometry is the one which is  usually used in clinical studies. 
   An ideal tomometer should have certain features. It must be 
able to give a reasonable and accurate intraocular pressure measurement. It 
should be convenient to use and easy to caliberate. It must have an easy 
standardization technique and must be free of maintenance problems. 
Tonometry basically of different types 
· INDENTATION TONOMETRY 
1. SCHIOTZ TONOMETER 
2. MUELLER’S TONOMETER 
3. ELECTRONIC TONOMETER 
· APPLANATION FIXED AREA TONOMETERS 
1. GOLDMANN’S TONOMETER 
2. NONCONTACT TONOMETER 
3. OCULAR RESPONSE ANALYSER 
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· APPLANATION FIXED FORCE TONOMETERS 
 MAKLAKOFF TONOMETER 
· COMBINED APPLANATION AND INDENTATION 
TONOMETERS 
MACKAY MARG TONOMETER 
   PNEUMATIC TONOMETER 
· REBOUND TONOMETER 
· DYNAMIC CONTOUR TONOMETER 
 
PALPATION METHOD /DIGITAL TONOMETRY 
   Intra ocular pressure is measured by estimation of response 
of the eye to the pressure applied by the finger pulp. If felt firm on touch it is 
assumed to be normal intraocular pressure. If it gets easily indentented, low 
IOP and if hard on touch it is  assumed to be high intraocular pressure.  
 
SCHIOTZ TONOMETER 
   The Schiotz tonometer is the indentation tonometer which is 
in current use. It was invented in 1905 and continued to get  refined  till 1927. 
The instument was deviced by Hjalmer Schiotz. It was developed based on the 
principle that a force will indent into a softer object more than a harder object. 
The more the indentation the more the reading and lesser the intraocular 
pressure. 
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PARTS OF SCHIOTZ TONOMETER 
                                                            
 
Figure 2 : Schiotz Tonometer 
    The device consists of a footplate which is placed on the 
cornea of patients. A weighted vertical  plunger moves freely within the shaft 
of foot plate and it indents and sinks into the cornea. The extent of indentation 
depends on the intra ocular pressure.  It has a bent lever whose short arm 
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resting on the upper end of plunger and its long arm acts as a pointer needle. A 
handle for holding it in the vertical position is there. A scale on the top 
measures the indentation. The scale reading and the weight are converted to 
intraocular pressure. The more the plunger indents the cornea the more the 
reading and lesser the intra ocular pressure. Each scale unit is 0.5 mm 
protrusion of the plunger. 
PRINCIPLE  
   When the tonometer is placed on the eye ,the weight of the 
tonometer increases the actual intra ocular pressure to a higher value and it is 
this increased intraocular pressure value which is obtained from the scale 
reading. If the actual intraocular pressure is P0 the increased value is P1 ,the 
change in pressure from P0 to P1 is actually a reflection of the resistance of the 
eye or scleral rigidity to the displacement of fluid. 
IOP with tonometer in position (P1)= actual IOP (P0) + scleral rigidity(E) 
   Determination of actual intraocular pressure from the 
measured scale reading (P1) is done using a conversion table called 
Friedenwald conversion table. Friedenwald generated a formula for 
calculation of actual IOP, 
      
log P0= P1 –CΔV 
 where C is a constant-coefficient of ocular rigidity, value is 0.025 and ΔV is 
change in volume. 
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FRIEDENWALD’S  NOMOGRAM 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
TECHNIQUE 
  The cornea of the patient should be anaesthetized by a local - 
Scale reading 5.5g 7.5g 10g 15g 
3.0 24.4 35.8 50.6 81.8 
3.5 22.4 33.0 46.9 76.2 
4.0 20.6 30.4 43.4 71.0 
4.5 18.9 28.0 40.2 66.2 
5.0 17.3 25.8 37.2 61.8 
5.5 15.9 23.8 34.4 57.6 
6.0 14.6 21.9 31.8 53.6 
6.5 13.4 20.1 29.4 49.9 
7.0 12.2 18.5 27.2 46.5 
7.5 11.2 17.0 25.1 43.2 
8.0 10.2 15.6 23.1 40.2 
8.5 9.4 14.3 21.3 38.1 
9.0 8.5 13.1 19.6 34.6 
9.5 7.8 12.0 18.0 32.0 
10.0 7.1 10.9 16.5 29.6 
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anaesthetic, 4 % lignocaine. When the patient is in supine position the patient is  
asked to fix his vision at a target after which the patients eyelids are separated 
and the foot plate of tonometer is lowered to rest on anaesthetized cornea. 
Scale reading is noted. A weight of 5.5 gm is initially used so that the plunger 
must be able to move freely. If the scale reading is 4 or less then an additional 
weight is added to the plunger. Conversion table is used to convert the scale 
reading to actual IOP. 
  The advantages of the schiotz tonometer are that ,it is small and 
portable . It’s cost is affordable and it does not require slit lamp or electricity. 
The tonometer has an anodized scale mount which is resistant to sterilization. 
Hence Schiotz tonometer is still the most widely used tonometer. 
CALIBERATION 
   The instrument must be caliberated before each use by 
placing it on a polished wooden sphere and checking whether the value is zero. 
If not the instrument must be repaired. 
STERILIZATION 
   After each use the instrument should be disassembled and 
the   barrel cleaned in two pipe cleaners. The first one soaked in 70 % isopropyl 
alcohol or methylated spirit and the second one dry. The foot plate is cleaned 
with alcohol swab. All surfaces should be dried before use. It can also be 
sterilized by ultra violet radiation , steam or ethylene oxide. Some disinfecting 
solutions like hydrogen peroxide or bleach may damage the instrument. 
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SOURCES OF ERROR  
   As ocular rigidity varies from eye to eye the accuracy is 
limited. The Friedenwald conversion table is made on the average coefficient 
of ocular rigidity and hence eye which has a significant variation from this may 
give an erroneous value. Repeated measurements may lower the intraocular 
pressure value. A steeper or a thicker cornea may cause a greater displacement 
of fluid and can produce a falsely high value. 
LIMITATIONS 
INSTRUMENTAL ERRORS 
· Mechanical obstruction of plunger 
· Errors of standardization 
MUSCULAR CONTRACTIONS 
· Extra oxular muscle contraction increases the intraocular pressure 
· Accomodation decreases the intraocular pressure- when the patient looks 
on the tonometer accomodation comes into play. The ciliary muscle 
contraction facilitates the flow of aqueous and thus the intraocular 
pressure decreases. 
VARIATIONS IN THE VOLUME OF GLOBE 
· Varies in microphthalmos, buphthalmos, myopia etc.. 
  The disadvantages include  
· Ocular rigidity dependent and scale markings are not detailed 
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· Mostly require some local anaesthetic to place it 
· Technique may produce abrasions 
APPLANATION TONOMETRY 
   The applanation tonometer works on  the Imbert – Fick 
principle. It states that the pressure inside an ideal thin walled dry sphere is 
equal to force required to flatten its surface divided by the area of flattening. 
But the actual cornea is not an ideal sphere. The two extra forces acting on the 
cornea are the surface tension of the tear film pulling the tonometer towards the 
cornea and the resistance of corneal rigidity. These two forces cancel each 
other when the corneal diameter is 3.06mm. 
   Goldmann’s tonometer  consist of a double prism mounted 
on a slit lamp which works on the principle of applanation. This prism 
applanates the cornea in an area of 3.06 mm. After topical anaesthesia the tear 
film is stained with the flurescein dye. The Biprism is advanced until it touches 
the apex of cornea. At this point two fluorescent semi circles are viewed 
through the prism. Applanation force is adjusted so that the inner edges of the 
two circles meet. The intraocular pressure is then found out by multiplying the 
dial reading with 10. 
   The Perkinn’s tonometer uses the same principle and 
biprisms as Goldmann tonometer.  
   The Non contact tonometer is another type of applanation 
tonometer where corneal flattening is made by a jet of air and corneal 
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applanation found out by a photo cell. The intraocular pressure is calculated 
from the dimensions of air jet. 
   Ocular Response Analyzer analyses the signals obtained 
from the corneal tissue and measures the biochemical properties of the cornea. 
It uses a bi-directional applanation process to measure the pressure of eye. 
   The  advantages of applanation tonometer are: 
More accurate than Schiotz,  accepted norm for IOP measurement ,easy to use. 
    The disadvantages include : 
 It is not portable, may cause abrasions, requires sterilization after each use. 
    
   The Mackay Margg tonometer is a combined indentation 
and applanation tonometer. It  has a plunger diameter of 1.5 mm and a 
surrounding sleeve is of 3mm diameter. The force required to keep the plate 
flush with the sleeve is electrically monitored. The Tonopen is a handheld 
Mackay Margg tonometer which is computerised. 
   Pneumatic or air tonometer is a more recent development 
in which both indentation and applanation works. Here an air jet at a constant 
pressure from a distance indents the cornea and a photocell measures the light 
beam reflected from the cornea. But it is highly expensive. 
   The Dynamic Contour Tonometer is a slit lamp mounted 
device which measures intraocular pressure independent of corneal rigidity and 
thickness. It uses the principle of contour matching instead of applanation. It’s 
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tip cntains a miniature pressure sensor. When the contour of cornea and 
tonometer matches the pressure measured becomes equal to the intraocular 
pressure.  
   Rebound tonometer measures intraocular pressure  by 
bouncing a small plastic tipped metal probe against the cornea. It uses an 
induction coil to magnetize the probe and fire it against the cornea. 
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PHARMACOLOGY OF SUCCINYL CHOLINE 
STRUCTURE 
    The depolarizing neuro muscular blocker succinyl choline 
has two acetyl choline molecules linked back to back through acetate methyl 
group. It acts like acetylcholine  and stimulates the cholinergic receptors at the 
neuro- muscular junction and opens the ion channels in the acetyl choline 
receptor. 
 
Figure 3: Chemical structure of succinylcholine 
MECHANISM OF ACTION 
PHASE 1 BLOCK 
    Succinyl choline is an agonist at Acetyl choline receptor. 
The two quaternary ammonium radicals bind to the two alpha subunits of 
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nicotinic receptor and deploarization occurs. Once acetyl choline receptor 
activation and membrane depolarisation occurs the voltage gated membrane 
channels sense the depolarization and they first open and then close and become 
inactivated. The membrane potential has to be again reset for the channels to get 
activated again. This is a very rapid process for acetyl choline as it is 
metabolized by acetylcholinesterase at the synaptic cleft. But succinyl choline is 
not metabolized by acetylcholinesterase and thus a prolonged activation of 
acetylcholine receptor occurs. The sodium receptors at the end plate and peri 
junctional zone remains inactivated and thus neuro muscular transmission is 
blocked.  
   Depolarization block is otherwise called as Phase 1 block or 
accomodation block. The initial fasciculation produced is as a result of 
prejunctional action of succinyl choline causing stimulation of acetyl choline 
receptors and repetitive firing and release of neuro transmitter. As it diffuses 
away from the neuro muscular junction and metabolized by pseudo choline 
esterase  its action decreases and recovery occurs. Prolonged exposure of neuro 
muscular junction to acetyl choline leads to Phase 2 block or Desnsitization 
block. 
PHASE 2 BLOCK 
   This occurs mainly after repeated bolus doses or prolonged 
infusion doses of succinyl choline. It can also occur after a single dose in a 
person with atypical pseudocholinesterase. It has all the features of a 
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competitive blockade like fade of train of four, tetanic fade or post tetanic 
potentiation. After the initial depolarization the membrane potential returns to 
resting state even though the neuro muscular junction is still exposed to the 
drug. Possible explanations for Phase 2 block is  
· Desentization of post junctional receptor. 
· Reduced synthesis and mobilisation of acetyl choline due to pre synaptic 
blockade. 
· Activation of sodium potassium ATP ase pump bringing potassium into 
the cell in exchange of sodium- and thus post junctional membrane 
potential moves in a direction of normal though the neuro muscular 
junction is still exposed to the drug. 
 
PHARMACOKINETICS AND PHARMACODYNAMICS 
    Succinyl choline has a very rapid onset of action and an ultra 
short duration of action. The ED 95 (dose causing 95 % suppression of neuro 
muscular blockade)  is 0.3-0.5 mg/kg  for an adult.  It is 0.7-0.8 mg/kg in infants 
where as in children it is 0.5 mg/kg. The intubation doses are 3-5 times greater 
than ED95 and hence about 1 mg/kg in an adult. Administration of 1 mg/kg of 
succinyl choline causes  complete suppression of response to neuro muscular 
stimulation in about 1-1.5 minutes. 
    The extremely short duration of action of Succinyl choline is  
because of the rapid hydrolysis by pseudocholinesterase. It ismetabolized to  
37 
 
succinyl monocholine which is a much weaker neuro muscular blocker. 
Thereafter it gets further metabolized to succinic acid and choline. The enzyme 
pseudocholinesterase has an enormous capacity to hydrolyze the drug in a very 
rapid rate so that only a very small amount of the injected drug reaches the 
neuromuscular junction. But since the enzyme is not present in the 
neuromuscular junction  it’s action is terminated by diffusion of the drug from 
the neuromuscular junction back into circulation. Pseudocholinesterase thus 
influnce the rate of hydrolysis of drug and hence the onset and duration of 
action of drug. The elimination half life of the drug is about 47 seconds. 
    The enzyme pseudocholinesterase is normally sythesized by 
the liver and also is found in plasma. The number of substrate molecules 
metabolized per unit time is used to express the activity of the enzyme in 
international units. The duration of succinylcholine induced paralysis used to 
get prolonged if the patient has an atypical pseudocholinesterase which is 
determined by an abnormal genetic variant. Dibucaine inhibits the normal 
pseudocholinesterase in a greater extent(80%) than it inhibits the abnormal 
pseudocholinesterase(20%).  Hence the Dibucaine number is used to find out 
the genetic makeup of a patient with respect to pseudocholinesterase. In most of 
cases the abnormal variant is due to a substitution error where a single 
aminoacid is erroneously substituted. 
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SIDE EFFECTS 
CARDIOVASCULAR EFFECTS 
1.Dysrhythmias  
   Succinylcholine stimulates the nicotinic receptors in the  
sympathetic and parasympathetic ganglia and also the muscarinic receptors in 
the sinus node of heart. Hence sinus bradycardia , junctional rhythms and 
ventricular dysrhythmias are manifested. 
Sinus bradycardia 
   Caused by the stimulation of cardiac muscarinic receptors in the 
sino atrial node. The higher incidence of bradycardia after a second dose of 
succinylcholine suggest that the  products of hydrolysis ,succinylmonocholine 
and choline may sensitize the heart to a subsequent dose. 
Nodal rhythms 
    This may probably be due to the greater stimulation of 
muscarinic receptors in the sinus node which suppress the sinus mechanism and 
allowing the atrioventricular node as the pacemaker. 
Ventricular dysrhythmias 
    The concentrations of catecholamines and potassium 
increases after succinylcholine administration and this may be a possible 
mechanism for the ventricular dysrhythmias. 
2.Hyperkalemia 
    The administration of succinylcholine to a healthy person  
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will increase the plasma potassium concentration by approximately 0.5 mEq/dl. 
Severe hyperkalemia have been reported in patients with denervation injuries, 
peripheral denervation, stroke, trauma,burns , prolonged immobility etc .. In 
burns patients, a  judicious avoidance of succinylcholine from 24 hours from the 
thermal injury to approximately 1-2 years post injury is advocated. In case of 
trauma ,studies have proved that the potassium elevating response of 
succinylcholine can occur upto 60 days following a major trauma where as in a 
case of nerve damage or neuromuscular disease,the  most vulnerable  period for 
hyperkalemia is within the first 6 months. This period is prolonged in case of a 
progressive disorder like muscular dystrophy.  Potassium loss via proliferation 
of extra junctional receptors may be a possible explanation. Hyperkalemia has 
also been reported in children with undiagnosed myotonia and muscle 
dystrophies. 
3.Fasciculations  
    The incidence of fasciculations after administration of 
succinylcholine is very high (60-90 %). The nerve fibre terminals contain 
acetylcholine receptors which will control the neuromuscular contraction by 
adjusting the availability of the number of acetylcholine vesicles. 
Succinylcholine activates and depolarize these receptors and this depolarization 
is strong enough in such a way that an action potential is generated and it will 
spread to all the muscle fibres supplied by the nerve. This presynaptic 
mechanism of succinylcholine  is the mechanism accepted for the involuntary 
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contractions or fasciculations. A small dose of non depolarizing neuromuscular 
blocking drug  given 3-5 minutes before succinylcholine (precurarization) is  
effective in preventing this as non depolarising neuro muscular blocking drugs 
block the presynaptic receptors. 
4.Increased intraocular pressure 
    It causes an increase of intraocular pressure of 5-15 mmHg . 
The increased intraocular pressure manifest within 1 minute after injection, 
peaks at 2-4 minutes and subsides after 6-7 minutes. 
5.Increased intra cranial pressure 
    Succinylcholine is known to cause increase in intracranial 
pressure. The clinical significance and mechanisms of this transient increase is 
not clear. A possible explanation is that  the contractions due to the presynaptic 
effect of succinylcholine is strong enough to increase the carbondioxide 
production which in turn leads to vasodialatation and increase of intracranial 
pressure. 
6.Myalgia 
    It has an incidence of about 0.2-90 %.This is mainly due to 
the unsynchronized contractions of adjacent muscle fibres. Pretreatment with a 
small dose of non depolarising muscle relaxants may be useful to prevent 
myalgias. 
7.Increased Intragastricpressure 
   This may be due to the fasciculations of the abdominal muscles.  
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Moreover the acetylcholine like effect of succinylcholine is also responsible for 
the increase in intra gastric pressure. An intragastric pressure of 28 cm H2O is 
needed to overcome the competence of the gastro esophageal junction in normal 
cases. But in situations like pregnancy, hiatus hernia, ascites etc; where the 
normal angulation of oesophagus itself is altered , an intra gastric pressure of 15 
cm H2O itself can cause the regurgitation of gastric contents. hence lead to asp 
8.Masseter spasm 
   This is probably due to the exaggerated contractile response at the 
neuro muscular junction. 
 
9.Anaphylaxis 
   Succinylcholine has been incriminated as the trigger of many types 
of allergic reactions. The incidence is not correctly known, but is probably of 
the order 1:5000 to 1:10000. 
CLINICAL USE 
   Its main use is to facilitate tracheal intubation. The rapid onset of 
action and very short duration of action makes it the ideal muscle relaxant for 
rapid sequence induction. In adults 1 mg/kg within 1-1.5 minutes after induction 
provides excellent intubating conditions. Children are slightly more resistant 
than adults and a dose of 1.5- 2 mg/kg is usually rquired. 
CONTRAINDICATIONS 
    Extensive damage to spinal cord, extensive burns, malignant  
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hyperthermia muscular dystrophy and previous anaphylactic reactions to the 
drug are all absolute contraindiactions to the use of the drug. 
   And the drug must be cautiously used in conditions like 
severe trauma, cerebrovascular accidents,hyperkalemia, prolonged immobility 
,sepsis etc 
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PHARMACOLOGY OF DEXMEDETOMIDINE 
    Dexmedetomidine was  approved by  FDA in the  year 1999 
in U.S.Dexmedetomidine an   imidazole  compound, is a  pharmacologically   
active  S enantiomer of medetomidine which is a veterinary anaesthetic. The 
empirical formula is C13H16N2HCl and the molecular weight is 236.7. it has a 
Pka of 7.1. And it is chemically S)-4-[1-(2,3-dimethylphenyl) ethyl]-3H 
imidazole. 
STRUCTURE 
 
Figure 4: Structure of Dexmedetomidine 
 
PHYSICO CHEMICAL PROPERTIES 
    It is a white powder soluable in water. Preservative free 
dexmedetomidine is available in ampoules in various strengths for intra venous 
use. It can also be used for spinal and epidural anaesthesia . 
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MECHANISM OF ACTION 
    Dexmedetomidine is a highly selective alpha 2 agonist with 
an α2 :α1 binding ratio of 1620 :1. Its alpha 2 receptor selectivity is 8 times that 
of clonidine. Action on various  alpha 2 receptor subtypes accounts for the 
varied pharmacodynamic effects of the drug. Alpha 2 A receptor agonism is 
responsible for the effects like sedation, hypnosis, analgesia,sympatholysis 
,neuroprotection and inhibition of insulin secretion. Alpha 2 B receptor action 
promotes suppression of shivering, analgesia at spinal cord levels and peripheral 
vasoconstriction which inturn causes the transient increase in blood pressure. 
Alpha 2 C is associated with modulation of cognition, sensory processing, mood 
and stimulant induced locomotor activity  and epinephrine outflow regulation 
from adrenal medulla. Inhibition of norepinephrine release is effected by all the 
three sub types of alpha 2 receptor. 
    The mechanism of action is unique and differs from the rest 
of sedative drugs. The highest density of alpha 2 receptor is found in locus 
cerulus which is the predominant noradrenergic nuclei of the brain stem and an 
important modulator of vigilance. The locus cerulus is also the site of origin of 
medullospinal noradrenergic pathway which plays an important role in 
nociceptive neuro transmission. Presynaptic activation of alpha 2 receptors in 
locus cerulus inhibits the noradrenaline release and produces the sedative and 
hypnotic effect. It also terminates the propagation of pain impuses leading to 
analgesia. Post synaptic activity of alpha 2 receptors result in reduced  
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sympathetic activity and leads to hypotension and bradycardia.
    At the spinal cord level
lamina 2) the alpha 2 receptor stimulation
nociceptive neurons and inhibition of rel
important mechanism for analgesia 
mechanisms exist. 
 
Figure 5: Physiology of various alpha 2 receptors
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PHARMACODYNAMICS 
    Dexmedetomidine is considered as a full agonist at alpha 2 
receptor than clonidine which is a partial agonist. The selectivity is dose 
dependent; at low- medium doses and slow infusions it is highly alpha 2 
selective , where as high doses or rapid infusions are associated with both alpha 
1 and alpha 2 effects. 
CENTRAL NERVOUS SYSTEM 
SEDATION, HYPNOSIS, ANXIOLYSIS, AMNESIA 
    The dexmedetomidine causes dose dependent effects in 
sedation and anxiolysis. The sedation provided by the drug is quite unique as it 
differs considerably from the sedative effects of other GABA- ergic drugs. 
Arousability is maintained even with deep levels of sedation in case of 
dexmedetomidine while other drugs acting through GABA receptors, like 
midazolam or propofol produces a clouding of consciousness. The sedation 
produced almost resembles that of normal sleep in case of dexmedetomidine. 
ANALGESIA 
    It produces analgesia by its action on both spinal cord levels 
and supra spinal levels. It reduces the opioid requirement. 
RESPIRATORY EFFECTS 
    Dexmedetomidine is able to produce sedation, hypnosis and  
axiolysis  without  causing  any    clinically   significant   respiratory depression. 
The change in  ventilation is similar to that observed during normal sleep. But 
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co- administration of other sedatives , opioids or hypnotics may produce 
additive effects. 
CARDIOVASCULAR EFFECTS 
    Dexmedetomidine does not produce any direct effect on 
heart. After a bolus dose of 1 μg/kg body weight it seems to produce a biphasic 
response. It initially results in a transient increase in blood pressure and in turn a 
reflex decrease in heart rate in healthy adults. This occurs due to the stimulation 
of peripheral alpha 2B receptors in vascular smooth muscles.  This may be 
attenuated by a slow infusion of dexmedetomidine over 10 minutes. The initial 
effects last for 5 – 10 minutes and following this a decrease in blood pressure 
occurs. It is mainly due to the inhibition of central sympathetic outflow. 
    The baroreceptor reflex is well preserved in patients 
receiving dexmedetomidine. However dexmedetomidine can result in severe 
cardiovascular supression leading to bradycardia and hypotension rarely. The 
incidence of post operative bradycardia is reported to be as high as 40 %. 
Usually these temporary effects are easily treatable by atropine, ephedrine or 
volume infusions. 
EFFECT ON INTRA OCULAR PRESSURE 
    Dexmedetomidine reduces intra ocular pressure. The direct  
vasoconstrictor effect on the afferent blood vessels of  ciliary body is 
responsible for the decreased aqueous humour production. It also reduces the 
sympathetically mediated tone of ocular drainage system and thus facilitates the 
48 
 
drainage of aqueous humour. The hemodynamic effects of dexmedetomidine 
may also be responsible for the intraocular pressure lowering effect. 
 
EFFECT ON ADRENO COTICO TROPHIN HORMONE SECRETION 
    Cortisol’s response to ACTH secretion may be reduced after 
prolonged use of dexmedetomidine. But the level of inhibition from studies 
seems to be clinically insignificant. 
EFFECT ON RENIN RELEASE 
    The renin secretion is stimulated by beta receptors and 
inhibited by alpha 2 receptor agonists. 
EFFECT ON INSULIN RELEASE 
    The alpha 2 stimulation has shown to inhibit insulin release 
but the clinical significance of the effect has not been studied and proven. 
EFFECT ON THERMOREGULATION 
    Dexmedetomidine and other alpha 2 agonists suppress 
shivering. This may probably be due to the central effect on thermoregulatory 
centers in hypothalamus. 
EFFECT ON RENAL FUNCTION 
    It inhibits the action of ADH on collecting ducts and thereby 
produces a diuretic effect. 
PHARMACOKINETICS 
    After intravenous administration it has an onset of action at 
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10- 15 minutes. The peak action after a continuous infusion occurs within 1 
hour.It has a distribution half life of 6 minutes and elimination half life between 
2 -2.5 hours.The drug is highly protein bound (94 %) and 6 % is free fraction. It 
has a steady state volume of distribution of 118L.  It has a rapid distribution and 
extensive metabolism in liver. It undergoes conjugation (41 %) or n-
methylation(21 %) or hydrolysis followed by conjugation.  Dose adjustments 
are required in patients with liver failure.After an intramuscular administration 
the time to maximum concentration in the blood is 1.7 hours and bioavailability 
is 73 %. It has a higher bioavailability when administerd by relatively non 
invasive buccal or nasal route. 
PERIOPERATIVE CLINICAL USES OF DEXMEDETOMIDINE 
PREMEDICATION 
    Dexmedetomidine is used as a sedative, anxiolytic and 
analgesic in terms of premedication.   It reduces thiopentone requirement and 
the requirement of volatile anaesthetics.It attenuates sympathetic response 
during laryngoscopy and intubation. Dexmedetomidine  reduces intra ocular 
pressure. The drug also reduces plasma catecholamine concentration.It also 
improves the perioperative hemodynamic stability of the patient. 
REGIONAL ANAESTHESIA 
   Epidural administration promotes synergism with local 
anaesthetic prolonging the  duration of sensory and motor blockade,post 
operative  
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analgesia, prevention of post operative shivering without confering any 
additional co morbidities.Intrathecal  administration of  dexmedetomidine 
prolongs the duration of sensory and motor blockade. 
  Addition of 0.5μg/kg body weight in intravenous regional 
anaesthesia improves the quality of anaesthesia and analgesia. 
MONITORED ANAESTHESIA CARE 
  Dexmedetomidine provides easy arousability with preserved 
orientation , mild analgesia  and anxiolysis without any respiratory depression 
SOLE ANAESTHETIC AGENT 
   De xmaedetomidine has been used as a sole anaesthetic 
agent upto doses of 10 μg/kg/hr.Certain neuro surgical procedures require a  
hemodynamically stable, sedated and calm patient who is awake and 
cooperative enough to perform certain neurocognitive and neuromotor tests on 
demand. This neurophysiological profile is achieved by dexmedetomidine. 
   It is also an ideal and safe agent for controlled hypotension. 
It has an excellent use in surgeries like scoliosis correction, septoplasty, 
tympanoplasty, maxillofacial surgeries etc..  
POST OPERATIVE PERIOD 
   The sedative and sympatholytic effect of dexmedetomidine 
is useful in reducing the incidence of post operative myocardial ischemic 
events in high risk patients undergoing non cardiac surgery. It also reduces post 
operative shivering. 
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PAEDIATRIC AGE GROUP 
   Addition of 2 μg /kg body weight of dexmedetomidine to 
caudal analgesia is beneficial in terms of the analgesia effect.It has an emerging 
novel use for opiods or benzodiazepines withdrawal  in pediatric age group.  
INTENSIVE CARE UNIT 
   It provides adequate sedation with minimal respiratory 
depression and also useful for weaning of patients from ventilator.Extubation 
can  be done even without discontinuing the infusion as it prevents emergence 
delirium and agitation. The drug has a potential for tratment of alcohol 
withdrawal in brain trauma patients. This neuroprotective effect is attributable 
to maintenance of sleep and ventilatory architecture.  
   An emerging role of dexmedetomidine is its use as an ideal  
sedative in facilitating awake fibre optic intubation. Especially in critically 
difficult airway situations, dexmedetomidine provides benefit as an excellent 
sedative providing a calm unagitated patient without a risk of respiratory 
depression. 
ADVERSE EFFECTS 
   Other than bradycardia and hypotension it has side effects 
like hypertension after loading dose, dystonic movements, atelectasis, nausea 
and vomiting, dry mouth, tachycardia, atrial fibrillation, haemorrhage,acidosis, 
agitation, confusion etc..After abrupt discontinuation from prolonged infusions 
withdrawal phenomenon is reported with hypertension, tachycardia,  
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emesis,agitation, dilated pupils,diarrhoea, increased muscle tone and seizures. 
   Caution should be exercised when using in patients who are 
volume depleted , vasoconstricted or having heart block.  
DOSAGE AND ADMINISTRATION 
   It is given as an intravenous bolus dose of 0.5-1 μg/kg over 
 10 minutes followed by a continuous infusion of 0.2-0.7 μg/kg/hr. The 
maintenance dose is titrated until sedation is reached. 
   Alpha 2 agonists may provide an attractive option as  an 
anaesthetic adjunct due to it’s anaesthetic sparing and hemodynamic stabilizing 
effects. Alpha 2 agonists does not affect the synthesis, storage and metabolism 
of the neurotransmitter and hence the hemodynamic side effects may be 
reversed with specific vasoactive drugs.  The unique mechanism of action, 
pharmacokinetic properties and the availability of an antagonistic agent 
Atipamezole makes it an almost ideal drug in an ICU and anaesthesia setting. 
Dexmedetomidine have promising scope in the future in the fields of 
neuroprotection, cardioprotection and renoprotection including pediatric age 
groups. 
 
 
 
 
53 
 
REVIEW OF LITERATURE 
    Succinylcholine was introduced into clinical practice in the 
year 1952. Since then it is the most widely accepted drug for rapid sequence 
induction because of it’s fast onset of action and excellent intubating conditions. 
But however it is associated with rise in intra ocular pressure. 
    The rise in intra ocular presurre associated with 
succinylcholine was first reported some 61 years back, as early in 1953 
Hoffmann reported that succinylcholine increases the intraocular pressure. In 
1955 Lincoff observed that succinylcholine administered for open globe 
injuries was associated with vitreous loss. This was confirmed by many other 
authors also. 
    Since then various methods have been used to attenuate the 
effect of  succinylcholine  on intraocular pressure.   Carballo et al in 1965 
suggested  the use of 500 mg I/V acetazolamide ,a carbonic anhydrase inhibitor 
preoperatively for reducing the effect of succinylcholine on intraocular pressure. 
Subsequently it was found that such acetazolamide premedication may increase 
the choroidal blood flow  by dialating the choroidal blood vessels and it may 
only mask the rise in intraocular pressure caused by succinylcholine. 
    Miller et al in 1968 using indentation tonometry advocated 
the use of dTc and gallamine pretreatment for blunting the rise of intraocular 
pressure associated with succinylcholine.   Myers and Bowen using the  
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applanation  tonometer were unable to confirm the same findings. 
    In 1979 Verma et al studied with indentation tonometer and 
suggested that 10 mg self taming dose of succinylcholine could prevent the rise 
in intraocular pressure associated with  subsequent  administration of full dose 
of succinylcholine. In 1980 Myers refuted the claim with another controlled 
study. 
    In 1979 Smith et al advocated the use of I/V lignocaine 
pretreatment 1-2 mg/kg for attenuating the hemodynamic responses  associated 
with laryngoscopy and intubation.   
    In 1981 Cunningham et al studied the effects of 0.1 mg/kg 
diazepam pretreatment which prevented subsequent rise in intraocular pressure 
following succinylcholine and intubation. Cook J H et al reported that 0.05 
mg/kg diazepam pretreatment prevented the rise of intraocular pressure 
associated with succinylcholine. 
    Many studies have been done at present on the effects of 
nondepolarising neuro muscular blockers  as a pretreatment in  preventing the 
rise of succinylcholine induced rise of intraocular pressure. Many studies 
refuting this effect have also been published. 
    In 1989 Indu et al advocated the use of sublingual 
nifedipine for the attenuation of rise of intraocular pressure associated with 
succinylcholine. The mean rise of ocular pressure from the baseline in the 
control group post intubation was  7.82 mmHg compared to 0.15 mmHg in  
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sublingual nifedipine pretreated group. 
    In 1993 Kelly et al did a study on 15 patients undergoing 
elective ennucleation after all the extraocular muscles detached in a diseased 
eye and compared with a normal eye with intact extra ocular muscles. Baseline 
intraocular pressure was comparable in both groups. After succinylcholine 
administration there was a rise in intraocular pressure in both groups and no 
major difference in the peak intraocular pressure attained in both diseased eye 
and normal eye. Hence they made a conclusion that extraocular muscles do not 
contribute to the rise in intraocular pressure associated with succinylcholine. 
    In 2007 Zahedi et al compared the effects of oral clonidine  
3μg/kg and diazepam 0.15 mg/kg premedication on the rise of intraocular 
pressure and hemodynamic stress response to succinylcholine and intubation. 
They found that the reduction in intraocular pressure was more with clonidine 
pretreatment compared to diazepam at all times after succinylcholine 
administration. 
REVIEW STUDIES OF DEXMEDETOMIDINE AND INTRAOCULAR 
PRESSURE CHANGES 
    Jakkola M L et al in 1992 conducted a randomized double 
blind study on 30 ASA 1or 2 patients undergoing cataract surgery and studied 
the effects of intravenous dexmedetomidine on intraocular pressure , 
sympathetic response and anaesthetic requirements following succinylcholine 
and intubation. The patients were randomly allocated to receive 10 minutes 
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before induction either dexmedetomidine 0.6μg/kg  or an equal volume of saline 
I/V as pretreatment over 1 min. Non invasive systolic B.P and diastolic B.P , 
heart rate and intraocular pressure were measured at specific time intervals. 
Intraocular pressure was measured with a schiotz tonometer. General 
anaesthesia was standardized for all patients. After dexmedetomidine 
premedication there was a 62 % reduction in plasma  noradrenaline 
concentrations and 34 % reduction in IOP. After intubation there was a 18 % 
reduction in heart rate and 27% reduction in intraocular pressure in the 
dexmedetomidine pretreated group. Upto 10 minutes after intubation the 
maximum systolic and diastolic B.P were also significantly lesser in the 
dexmedetomidine premedicated group. The induction dose of thiopentone and 
the supplemental dose of isoflurane were also significantly lesser in 
dexmedetomidine group. 
     In 1993 Virkkila m et al conducted a study on 35 
patients undergoing day care cataract surgery under peri ocular block to assess 
the effects of dexmedetomidine premedication on intraocular pressure , 
hemodynamics, anxiolysis,sedation and dryness of mouth. Five different doses 
of the drug were used ;0.25 μg/kg,0.5 μg/kg,0.75μg/kg,1.0μg/kg,and 1.5μg/kg. 
The drug was given intramuscularly 60 minutes before induction.The 1 μg/kg 
dose produced a 32 % reduction in intraocular pressure. There was a moderate 
sedation but it was not associated with any hemodynamic changes. 
     In 1994 Virkkila M et al conducted a double blinded  
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randomized control study on 90 patients undergoing day care cataract  surgery 
under peri ocular block. He compared the effects of dexmedetomidine  1μg/kg , 
midazolam 20 μg/kg and saline placebo on the intraocular pressure changes. 
The drug was injected I/M into deltoid muscle 45 minutes before periocular 
block. Dexmedetomidine  1 μg/kg reduced the intra ocular pressure before, 
during and after surgery. In contrast midazolam did not produce any difference 
from saline placebo. Both dexmedetomidine and midazolam produced same 
degree of sedation. Dexmedetomidine produced a slightly reduced B.P and heart 
rate throughout the study. Hence they concluded that dexmedetomidine 1 μg/kg 
is an effectve premedicant for controlling intraocular pressure, and achieving 
sedation with minimal cardiovascular effects. 
    In 2005 Seluck M et al did a randomized trial to study the 
effects of dexmedetomidine infusion on intraocular pressure and sedation 
among 44 ASA 1-2 patients undergoing outpatient cataract surgery under 
periocular block. Patients were allocated into two groups,group 1 received 
dexmedetomidine 1μg/kg/hr  I/V given over 10 minutes followed by a 
continuous infusion of  0.2 μg/kg/hr  ;where as group 2 received same dose of 
normal saline. Intraoperative heart rate, systolic B.P, diatolic B.P, SPO2, visual 
analog scale, and sedation scale were recorded every 5 minute before and during 
surgery and 15 min interval thereafter. Intraocular pressure was measured 
before, during and after surgery. Alderete  scoring was done after procedure. 
Heart rate, blood pressure and intraocular pressure were significantly reduced in 
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dexmedetomidine group. Intraocular pressure was reduced by 28 % when 
measured after surgery. Alderete score was lesser in group 1 than placebo. Post 
operative VAS was also significantly lower in the study group. 
    In 2006 Abdalla M et al conducted a study on 40 patients 
undergoing opthalmic surgeries under local anaesthesia with dexmedetomidine 
infusion. The total number of patients were allocated into 20 each ,group A who 
received dexmedetomidine 0.5 μg/kg/hr for 10 minutes followed by 0.2 
μg/kg/hr infusion for 50 minutes and group B same dose of saline. Heart rate, 
systolic B.P and diatolic B.P were measured at various time intervals before and 
during infusion and intraocular pressure measured before and after the surgery 
with schiotz tonometer. They observed that intraocular pressure, heart rate, 
systolic B.P and diastolic B.P were significantly lower in dexmedetomidine 
group than control group. 
    In 2007, Lee et al studied the effect of dexmedetomidine 
infusion as an adjuvant on isoflurane anaesthesia on patients undergoing 
elective vitreo retinal surgeries. The patients were allocated into two groups. A 
loading dose of 2.5 μg /kg/hr infusion was given to the study group  and same 
dose of saline to the control group over 10 minutes before induction . 
Anaesthesia was standardized with propofol, fentanyl induction. After induction 
a maintenance dose of 0.4 μg/kg/hr of dexmedetomidine infusion was given till 
30 minutes before the end of procedure. Anaesthesia was maintained with 
isoflurane, nitrous oxide and oxygen. Intraocular pressure was measured with a 
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tonopen before premedication and 1 minute after intubation. Heart rate , systolic 
B.P, diastolic B.P, mean arterial pressure were also recorded at specific time 
intervals. The M.A.P was comparable between the two groups except in the 
recovery phase. The heart rate was significantly lesser in the study group. 
However the intraocular pressure of both groups were reduced after propofol 
induction and the values were comparable.Hence they concluded that 
dexmedetomidine may be used without any hemodynamic fluctuations and that 
the effect of dexmedetomidine on  intraocular pressure is mainly due to its 
indirect  hemodynamic effect. 
    Ayoglu H et al conducted a study on 40 adult patients 
undergoing cataract surgery under regional anaesthesia to study the effect of 
dexmedetomidine sedation. The study group received a loading dose of 1 μg/kg 
dexmedetomidine for 10 minutes. When additional sedation was needed 
dexmedetomidine 2μg/ml for patient controlled sedation (PCS) was prepared. 
The PCS settings were a dose of 5μg and a lock out interval of 10 minutes. 
Additional doses were recorded. The parameters which were studied were 
intraocular pressure, hemodynamic variables, perception of pain during 
injection of local anaesthetics, intra operative Ramsay Sedation Scores and post 
operative Aldrete scores. The mean dexmedetomidine dose was 66.4 μg. The 
mean heart rate and B.P were found to be lower in the study group. After 
dexmedetomidine loading dose, intraocular pressure was also significantly  
reduced. 
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     In 2008 Mowafi et al conducted a study on 40 
patients undergoing elective non ophthalmic surgeries under general anaesthesia 
to investigate the effect of dexmedetomidine premedication on intaocular 
pressure after succinylcholine and intubation. The study group received a bolus 
dose of dexmedetomidine 0.6μg/kg body weight and the control group received 
saline over 10 minutes before induction. All patients were attached the standard 
monitors. IOP was measured by Schiotz tonometer. The authors observed that 
after dexmedetomidine premedication the intraocular pressure was reduced. 
Succinylcholine increased the intraocular pressurein both the study and control 
groups. However IOP in the study group was not significantly elevated from the 
baseline. Whereas in the control group the intraocular pressure was significantly 
elevated from the baseline value. They also observed that dexmedetomidine 
premedication blunted the sympathetic response during laryngoscopy and  
intubation. 
     In 2012 Xulili et al studied the effect of 
dexmedetomidine premedication in 60 children undergoing vitreoretinal 
surgeries. Anaesthesia was given with sevoflurane 1-2 %,supplemented with 
remifentanyl   0.2 μg/kg/min. Intraocular pressure  was measured after 
sevoflurane inhalation and 10 minutes after dexmedetomidine administration 
intravenously 0.5 μg/kg in the study group or normal saline in the control group. 
They observed that there was no significant difference in intraocular pressure 
between the two groups at the two  time points. In both groups the mean heart 
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rate and B.P reduced from the baseline after induction. The increase in the 
hemodynamic parameters from the baseline associated with extubation was 
diminished in the dexmedetomidine group than the control group. The 
emergence agitation was also lesser in the dexmedetomidine group. 
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MATERIALS AND METHODS 
    This was a prospective randomized controlled study. After 
ethical committee approval and informed written consent , the study was 
conducted in 60 eligible patients after explaining the procedure details to the 
patient. This study was conducted at Government Rajaji Hospital attached to 
Madurai Medical College. 
a) INCLUSION CRITERIA 
· Elective non ophthalmic surgeries under G.A 
· 18-60 years 
· Male or female 
· ASA 1 or 2 
· Intubation with first attempt 
b) EXCLUSION CRITERIA 
· >60 years of age and <18 years 
· BMI>30 
· Patients with Mallampatti class III/IV 
· History of systemic hypertension /diabetes mellitus /coronary 
artery disease  
· Patients with any acute or chronic eye disease or raised intraocular 
pressure. 
· Patients with any contraindication to succinylcholine 
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· Any other contraindication to dexmedetomidine like  
hemodynamic instability 
· History of any drug intake known to alter IOP 
· Patient’s refusal 
· Pregnancy 
METHODOLOGY 
   60 adult patients of ASA I or II undergoing elective non 
ophthalmic surgeries under  General anaesthesia meeting the inclusion criteria 
were selected. 
   The 60 patients were randomly divided into 3 groups of 20 
patients each. 
  GROUP C-  Control group to receive normal saline as   I/V 
      premedication 
  GROUP D4- Dexmedetomidine group to receive 0.4 μg/kg of  
       dexmedetomidne as I/V premedication 
  GROUP D6- Dexmedetomidine group to receive 0.6 μg/kg of  
        dexmedetomidine as I/V premedication 
   The study drug Dexmedetomidine was prepared by diluting 
1ml of  dexmedetomidine  from100 μg/ml ampoule to 49 ml of normal saline 
to a concentration of 2 μg/ml.  The study drug or normal saline in the 
respective groups was then given over 10 minutes. The drug was administered 
10 minutes before induction.The study drug solution was prepared by an 
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anaesthetic colleague outside the operating room, so that anaesthetist delvering 
G.A and performing IOP measurement and the patients were totally unaware of 
the drug being given to the patient. 
 
PREOPERATIVE EVALUATION 
   A routine pre anaesthetic assessment of the patient included 
history regarding the severity and duration of symptoms, history of any other 
systemic illness, history of any other previous surgeries. A detailed 
examination was done assessing the general condition, airway , nutritional 
status, weight and height of the patient. A thorough systemic examination of 
cardiovascular and respiratory system was made. 
   The following basic investigations like haemoglobin, urine 
examination for sugar ,albumin and microscopy, blood sugar, blood urea, 
serum creatinine, standard 12 lead ECG, echocardiography, serum electrolytes 
and X ray chest were done for all patients. 
   In the operating room intravenous cannulation was 
performed. Monitoring devices like NIBP, pulseoximetry probe, ECG 
electrodes, were attached and baseline vital parameters were recorded. Topical 
lignocaine 4% ,two drops were instilled into the cornea of each eye. Baseline 
inta ocular pressure was then measured with Schiotz tonometer by a trained 
ophthalmologist. 
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Figure 6:Picture showing the Measurement of the intra ocular pressure 
  
   Premedication with Dexmedetomidine from the prepared 
solution in a dose of  0.4 μg/kg or 0.6μg/kg to groups D4 and D6 respectively 
and normal saline to control group was administered over 10 minutes. 
   General anaesthesia was standardized in all the three groups. 
After preoxygenation for 3 minutes, patients were induced with injection 
thiopentone 5 mg/kg and injection succinylcholine 1.5 mg/kg 10 minutes after 
premedication. All three groups were then intubated with appropiate sized 
cuffed endo tracheal tubes using conventional laryngoscope. The patients were 
excluded if trachea was not intubated at the first attempt. 
66 
 
   Anaesthesia was maintained with nitrous oxide and oxygen, 
and injection atracurium. After the surgical procedure the patients were 
reversed with injection neostigmine 0.05 mg/kg and glycopyrrolate 0.01 
mg/kg. And after adequate suction the patients were extubated. 
PARAMETERS MONITORED 
  The following parameters were monitored and compared between 
all three groups. 
· INTRAOCULAR PRESSURE 
· HEART RATE 
· SYSTOLIC BLOOD PRESSURE 
· DIASTOLIC BLOOD PRESSURE 
· SPO2 
  Intra ocular pressure measured with Schiotz indentation tonometer 
and measured at the following time points. 
· Before premedication(baseline) 
· 10 minutes after premedication 
· 30 seconds after thiopentone sodium administration 
· 30 seconds after succinyl choline 
· 1 minute after intubation 
· 5 minutes after intubation 
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  Heart rate, systolic B.P, diastolic B.P, SPO2 were recorded with the 
multipara monitor. The recordings were done during the above mentioned time 
points and additionally at 10, 15, 30,45,60,75,90,105,and 120 minutes of the 
procedure. 
  Side effects like hypotension ,bradycardia, nausea ,vomiting etc in 
the intra operative and post operative period were studied. Fall in B.P >30 % 
was considered as hypotension and was treated with I/V fluids and ephedrine. 
Rate below 50 beats per minute was taken as bradycardia and  
treated with injection atropine I/V. 
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STATISTICAL ANALYSIS 
   
  The information collected regarding all  the selected cases were 
recorded in a master chart. Data analysis was done with the help of computer 
using Epidemiological Information Package (2010) developed by Center For 
Disease Control, Atlanta. 
  Using this software ,range, frequencies, percentages, means, 
standard deviations, chi square ‘t’ value and   'p'  values were calculated.  ‘t’  
test was used to test the significance of difference between quantitative 
variables and  Yate’s and Fisher’s chi square tests for qualitative variables.  
  A 'p' value less than 0.05 is taken to denote significant relationship. 
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OBSERVATIONS AND RESULTS 
Control group  : Patients who received Saline 
 D 4 group    : Patients who received 0.4 μg/kg of    
     Dexmedetomidine 
 D 6 group    : Patients who received 0.6 μg/kg of    
     Dexmedetomidine 
 
 
CHARACTERISTICS OF CASES STUDIED 
TABLE 1 : AGE DISTRIBUTION 
Group 
Age (in years) 
Mean SD 
Control Group 38.2 9.0 
D4 Group 39.5 9.7 
D6 Group 40.3 10.1 
‘p’ Value between 
Control & D4 Group 0.6642 
Control & D6 Group 0.492 
D4 & D6 Group 0.7997 
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  Mean age of the control group was 38.2 years
of D4 group was 39.5 years with a S.D of  9.7
years with a S.D of  10.1.  Age distribution of all three groups were comparable 
and there was no statistical difference among these groups.
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TABLE 2 : SEX DISTRIBUTION 
 
Group 
Sex 
Male Female 
No % No % 
Control Group 10 50 10 50 
D4 Group 11 55 9 45 
D6 Group 9 45 11 55 
‘p’ Value between 
Control & D4 
Group 0.5 
Control & D6 
Group 0.5 
D4 & D6 
Group 0.3762 
 
    
  50 % of control group, 55 % of group D4 and 45 % of group D6 
were males. 50 % of control group,45 % of group D4 and 55 % of group D6  
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were females.From the above table it was found that there was no statistical 
significance in the gender between the three groups.
the three groups were comparable.
SEX DISTRIBUTION
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TABLE 3. HEIGHT , WEIGHT AND BMI DISTRIBUTION 
 
   
   The table showes the weight, height and body mass 
index characteristics of the three groups.The mean body weight in the control 
group was 53.3 kg, of D4 group was 54.3 Kg and that of D6 group was 53.5 Kg. 
Group 
Height Weight BMI 
Mean SD Mean SD Mean SD 
Control 
Group 158.4 3.8 53.3 6.4 21.2 2.5 
D4 
Group 158.0 3.9 54.3 5.5 21.8 2.6 
D6 
Group 158.4 3.5 53.5 4.9 21.4 2.4 
‘p’ Value 
between  
Control 
& D4 
Group 
0.7759 0.581 0.4871 
Control 
& D6 
Group 
0.9658 0.8903 0.8663 
D4 & D6 
Group 0.735 0.6326 0.5852 
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The mean height of control , D4 and D6 groups were 158.4 cm, 158.0 cm and 
158.4 cm respectively.Mean BMI of the control gr
D4 was 21.8 and D6 was 21.4
all three groups were comparable.
HEIGHT , WEIGHT AND BMI DISTRIBUTION
 
0
20
40
60
80
100
120
140
160
HEIGHT(cms)
M
ea
n 
va
lu
es
CONTROL GROUP
oup was 21.2, that of group 
. The weight ,height and BMI distribution among 
 
      
 
 
 
 
 
 
 
 
 
 
 
WEIGHT(kgs) B M I
D4 GROUP D6 GROUP
 
75 
 
TABLE 4. ASA CHARACTERISTICS 
Group 
ASA 
1 2 
No % No % 
Control Group 10 50 10 50 
D4 Group 10 50 10 50 
D6 Group 10 50 10 50 
‘p’ Value between 
Control & D4 
Group 1.0 
Control & D6 
Group 1.0 
D4 & D6 
Group 1.0 
 
 
ASA distribution among all three groups were comparable with no significant 
difference 
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TABLE 5 : DURATION OF SURGERY 
Group 
 
Duration of surgery (minutes) 
Mean SD 
Control Group 91.5 23.8 
D4 Group 90.78 24.6 
D6 Group 90.68 24.6 
‘p’ Value between 
Control & D4 Group 0.9224 
Control & D6 Group 0.9224 
D4 & D6 Group 1.0 
 
  The mean duration of surgery among all three groups were 
comparable. Mean duration of surgery in control group was 91.5 minutes where 
as that of D4 was 90.78 minutes and of D6 was 90.68 minutes. 
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DURATION OF SURGERY
  The graph showing the comparison of the mean duration of 
surgery among all three groups.
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TABLE 6:INTRA GROUP COMPARISON OF INTRAOCULAR 
PRESSURE 
IOP Value at 
Value for ‘p’ Value between 
Control 
Group D4 Group D6 Group 
Control 
& D4 
group 
Control 
& D6 
groups 
D4 & 
D6 
Groups Mean SD Mean SD Mean SD 
Baseline 16.5 0.8 16.4 0.7 16.4 0.8 0.8863 0.9542 0.9366 
10 minutes 
after 
Premedication 
16.5 0.8 14.4 0.6 14.0 1.0 <0.0001 <0.0001 0.0805 
30 
secondsAfter 
Tliopentone 
15.1 0.6 13.1 0.8 12.6 0.7 <0.0001 <0.0001 0.0517 
30 
secondsAfter 
Succinyl 
Choline 
19.3 1.2 15.7 0.6 15.5 0.7 <0.0001 <0.0001 0.4094 
After intubation 
1 minute 20.6 1.0 16.0 0.4 16.0 0.5 <0.0001 <0.0001 0.6205 
5 minute 18.7 1.0 15.4 0.8 15.1 0.6 <0.0001 <0.0001 0.317 
 
  
   The baseline intra ocular presssure in all three groups were 
comparable. Statistical evaluation showed significant reduction in IOP in both 
the study groups D4 and D6 after premedication when compared to the control 
group. Comparison between D4 and D6 showed more IOP reduction with D6 
,but without any statistical significance. The mean IOP decreased in all three 
groups after thiopentone induction but the control group had significantly higher 
80 
 
IOP when compared to D4 and D6 . The mean IOP increased after 
succinylcholine and intubation in all three groups but in groups D4 and D6 it 
was never increased above the baseline value. The difference in IOP following 
succinyl choline,and after 1 minute and 5 minutes of intubation was statistically 
significant. 
CHANGES IN INTRA OCULAR PRESSURE 
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TABLE 7: CHANGES IN PULSE RATE 
Pulse Rate at 
Value for ‘p’ Value between 
Control 
Group D4 Group D6 Group Control & D4 
group 
Control 
& D6 
groups 
D4 & 
D6 
Group
s Mean SD 
Mea
n SD Mean SD 
Baseline 83.2 3.1 82.6 3.3 82.4 3.0 0.5272 0.4162 0.8815 
After 
Premedication 83.2 3.1 70.3 4.0 67.6 4.4 <0.0001 <0.0001 0.0492 
After 
Thiopentone 84.1 3.0 70.5 3.9 68.4 5.0 <0.0001 <0.0001 0.1447 
After 
Succinyl 
Choline 
85.2 3.0 71.5 3.7 69.2 4.9 <0.0001 <0.0001 0.1016 
After intubation 
1 minute 118.0 10.1 101.0 5.0 100.3 3.0 <0.0001 <0.0001 0.5679 
5 minute 103.7 4.4 94.2 3.4 98.3 3.9 <0.0001 <0.0001 0.0511 
10 minutes 88.8 9.7 82.5 3.2 82.0 4.0 <0.0001 <0.0001 0.6973 
15 minutes 83.5 3.2 81.9 3.8 83.0 4.3 0.1501 0.6792 0.3769 
30 Minutes 83.9 3.6 82.6 3.4 82.1 4.2 0.2307 0.1518 0.7116 
45 Minutes 82.1 4.1 82.8 4.5 82.9 4.6 0.6113 0.5666 0.945 
60 Minutes 83.0 3.5 82.9 4.0 81.2 2.9 0.9 0.0841 0.146 
75 minutes 83.8 3.9 83.8 4.5 81.7 5.0 0.8051 0.1482 0.1741 
90 minutes 85.2 5.9 83.1 4.1 80.8 4.7 0.1855 0.0825 0.1138 
105 minutes 81.5 5.2 80.4 5.5 83.3 5.6 0.538 0.3019 0.1085 
120 minutes 82.8 4.4 84.1 4.5 83.6 4.3 0.4032 0.5927 0.7485 
 
 The mean baseline heart rate in all three groups were 
comparable.  The mean heart rate after premedication with dexmedetomidine 
was significantly less in both the study groups and the reduction was 
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significantly more in D6 group. The mean heart rate in the study groups were 
significantly lesser when compared to control group after succinylcholine 
administration and after intubation. But between the two study groups D4 and 
D6 the mean heart rate was comparable after intubation. 
CHANGES IN PULSE RATE 
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TABLE 8:CHANGES IN SYSTOLIC BLOOD PRESSURE 
Systolic 
Blood 
Pressure at 
Systolic Blood Pressure of ‘p’ Value between 
Control 
Group D4 Group D6 Group 
Contr
ol & 
D4 
group 
Contro
l & D6 
groups 
D4 & 
D6 
Group Mean SD Mean SD Mean SD 
Baseline 125.1 4.6 125.0 7.8 125.5 7.7 0.9609 0.8431 0.8394 
After 
Premedication 125.7 4.4 117.6 6.9 105.9 5.0 0.0001 <0.0001 <0.0001 
After 
Thiopentone 120.2 5.3 115.4 6.3 108.8 5.7 0.0132 <0.0001 0.0013 
After Succinyl 
Choline 126.9 5.2 118.6 7.6 114.5 6.1 0.0003 <0.0001 0.0678 
After intubation 
1 minute 141.3 4.6 131.8 4.7 130.0 4.2 <0.0001 <0.0001 0.2082 
5 minute 136.0 3.7 127.6 5.1 126.4 6.8 <0.0001 <0.0001 0.5311 
10 minutes 135.0 5.7 121.8 6.7 125.5 7.7 <0.0001 <0.0001 0.1142 
15 minutes 128.1 4.2 125.9 4.9 128.1 4.2 0.1362 1.0000 0.1362 
30 Minutes 127.4 13.3 128.9 13.9 128.9 13.9 0.729 0.729 1.0 
45 Minutes 129.1 8.2 131.5 8.8 131.5 8.8 0.3783 0.3783 1.0 
60 Minutes 127.4 7.7 128.7 9.3 128.7 9.3 0.6335 0.6335 1.0 
75 minutes 119.8 28.7 126.0 13.8 126.0 13.8 0.3899 0.3899 1.0 
90 minutes 127.4 7.8 129.4 5.7 129.4 5.7 0.3497 0.3497 1.0 
105 minutes 122.1 12.9 125.5 13.5 125.5 13.5 0.4262 0.4262 1.0 
120 minutes 126.3 7.1 127.8 8.2 127.8 8.2 0.5503 0.5503 1.0 
  
   The mean baseline systolic blood pressure among all three 
groups were comparable  without any statistical significance. The mean systolic 
blood pressure was significantly reduced in both the study groups after 
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premedication when compared to control and the decrease in systolic B.P was 
significantly more in D6 group. The maximum reduction was seen after 
thiopentone administration. The systolic B.P  after intubation was signifiacntly 
more in control group when compared to the study groups. But there was no 
statistical significance between the two study groups regarding the systolic B.P 
after intubation. 
CHANGES IN SYSTOLIC BLOOD PRESSURE 
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TABLE 9 :CHANGES IN DIASTOLIC BLOOD PRESSURE 
Diastolic 
Blood 
Pressure  
Diastolic Blood Pressure in ‘p’ Value between 
Control 
Group D4 Group D6 Group Control & D4 
group 
Control 
& D6 
groups 
D4 & 
D6 
Groups Mean SD Mean SD Mean SD 
Baseline 83.5 9.8 83.8 9.4 83.5 9.3 0.9218 1.0000 0.9196 
After 
Premedication 83.6 9.3 73.8 6.6 69.0 3.3 <0.0001 <0.0001 0.0062 
After 
Thiopentone 82.5 9.8 71.1 4.8 68.7 2.8 <0.0001 <0.0001 0.0633 
After 
Succinyl 
Choline 
83.5 9.5 74.7 7.3 70.5 4.7 <0.0001 <0.0001 0.0379 
After intubation 
1 minute 104.7 6.5 84.9 8.4 82.6 7.5 <0.0001 <0.0001 0.3694 
5 minute 97.4 5.9 82.3 8.2 81.7 6.9 <0.0001 <0.0001 0.8029 
10 minutes 92.8 8.2 82.8 8.3 81.7 7.6 0.0005 <0.0001 0.6655 
15 minutes 82.8 10.0 80.5 9.1 81.8 8.7 0.4516 0.7374 0.6457 
30 Minutes 84.5 9.2 83.0 8.4 81.3 9.2 0.5938 0.2778 0.5443 
45 Minutes 83.4 8.6 82.1 8.3 82.5 7.6 0.6301 0.7286 0.8747 
60 Minutes 86.8 8.4 84.7 9.1 84.2 7.9 0.4532 0.3215 0.8536 
75 minutes 83.2 8.0 83.2 8.0 83.2 8.0 1.0000 1.0000 1.0000 
90 minutes 84.8 9.7 86.8 8.4 83.4 8.6 0.4915 0.6329 0.2158 
105 minutes 86.9 8.3 84.8 9.7 84.8 9.7 0.4681 0.4681 1.0000 
120 minutes 84.6 7.9 84.5 9.2 83.2 8.0 0.9623 0.5782 0.8363 
   
   The mean diastolic blood pressure before  premedication 
(baseline)   did not show any statistical significance. The mean  diastolic B.P 
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after premedication was significantly lesser in D4 and D6 and significanty 
greater reduction was observed in D6 group. The mean diastolic B.P after 
intubation was significantly increased in the control groups when compared to 
study groups. 
CHANGES IN DIASTOLIC BLOOD PRESSURE 
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TABLE 10 : CHANGES IN SPO2 
SPO2 at 
SPO2 in ‘p’ Value between 
Control 
Group D4 Group D6 Group 
Contr
ol & 
D4 
group 
Control 
& D6 
groups 
D4 & 
D6 
Grou
ps Mean SD Mean SD Mean SD 
Baseline 98.3 0.7 98.5 0.5 98.3 0.7 0.2122 1.0000 0.2122 
After 
Premedicati
on 
98.5 0.5 98.3 0.7 98.3 0.7 0.2122 1.0000 1.0000 
After 
Thiopentone 98.3 0.7 98.3 0.7 98.3 0.7 1.0 1.0000 1.0000 
After 
Succinyl 
Choline 
98.3 0.7 98.3 0.7 98.3 0.7 1.0 1.0000 1.0000 
After intubation 
1 minute 98.5 0.5 98.3 0.7 98.3 0.7 0.2122 0.2122 1.0000 
5 minute 98.3 0.7 98.3 0.7 98.3 0.7 1.0 1.0000 1.0000 
10 minutes 98.5 0.5 98.3 0.7 98.3 0.7 0.2122 0.2122 1.0000 
15 minutes 98.3 0.7 98.3 0.7 98.3 0.7 1.0 1.0 1.0000 
30 Minutes 98.3 0.7 98.3 0.7 98.3 0.7 1.0 1.0 1.0000 
45 Minutes 98.3 0.7 98.3 0.7 98.3 0.7 1.0 1.0 1.0000 
60 Minutes 98.3 0.7 98.3 0.7 98.3 0.7 1.0 1.0 1.0000 
75 minutes 98.3 0.7 98.3 0.7 98.3 0.7 1.0 1.0 1.0000 
90 minutes 98.3 0.7 98.3 0.7 98.3 0.7 1.0 1.0 1.0000 
105 minutes 98.3 0.7 98.3 0.7 98.3 0.7 1.0 1.0 1.0000 
120 minutes 98.3 0.7 98.3 0.7 98.3 0.7 1.0 1.0 1.0000 
    
  The mean baseline  SPO2 was comparable among all three groups.  
The  mean SPO2 after premedication between the control and study groups was  
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comparable. The mean SPO2 after intubation also did not show any statistical 
significance between the control and study groups. 
CHANGES IN SPO2     
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TABLE 11:COMPLICATIONS 
Complicat
ions 
 
Complications present in ‘p’ Value between 
Control 
Group 
(n=20) 
D4 
Group(n=2
0)  
D6 Group 
(n=20) Contr
ol & 
D4 
group 
Control 
& D6 
groups 
D4 
& 
D6 
Gro
ups Mean SD Mean SD Mean SD 
Bradycardia - - 1 5 2 10 0.5 0.2458 0.5 
Hypotension 1 5 2 10 2 10 0.5 0.5 1.0 
Dizziness - - - - 1 5 - 0.5 0.5 
Dry month 1 5 1 5 1 5 1.0 1.0 1.0 
Nausea - - - - - - - - - 
Shivering 1 5 - - 1 5 0.5 1.0 0.5 
 
 3 patients, one from the D4 group and 2 from the D6 group 
developed bradycardia. None from control group developed bradycardia. 5 
patients one from the control group ,  two from D4 and two from D6 group had 
hypotension. Total 3 patients had dry mouth, and 2 had post operative shivering.   
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COMPLICATIONS
There was no statistical signficance  when the incidence of complications were 
compared between the three groups.
0
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DISCUSSION 
  Patients with penetrating eye injury may present with full 
stomach. The main goal of anaesthesia in this situation is to rapidly secure an 
airway without increasing the intra ocular pressure. Succinylcholine which is 
used to facilitate the rapid sequence induction has the poential of increasing the 
IOP. Laryngoscopy and endotracheal intubation which are employed as a part of 
conduct of general anaesthesia are both noxious stimuli and are associated with 
stress response and hemodynamic responses. These may be manifested as 
tachycardia, hypertension , rise in intra ocular pressure etc.. The increase in 
intraocular pressure is transient and variable , may not be significant in a normal 
individual can be a very significant and fatal factor in a patient with an open 
globe injury. 
  Though rocuronium also has a very rapid onset of action and 
effects a fast onset of muscle paralysis it is not considered equivalent to 
succinyl choline for a patient with a difficult airway. 
 This is by far the most important indication for attenuation of 
the incease in intra ocular pressure and hemodynamic response to laryngoscopy 
and intubation in patients posted for emergency ophthalmology surgeries and 
patients with raised intraocular pressure. 
 Various methods have been used to attenuate the effects of  
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succinylcholine on intraocular pressure , but no modality is devoid of 
drawbacks and limitations. Hence a drug which can blunt the effects of 
succinylcholine, laryngoscopy and intubation on intraocular pressure with 
minimal adverse effects on intubating conditions and cardio respiratory 
parameters should be really useful and ideal for the purpose.  
 Dexmedetomidine was recently introduced in India (2009), and 
not many studies have been done in India regarding it’s IOP lowering effect. 
Hence the effects of dexmedetomidine in lowering intraocular pressure, and 
attenuation of hemodynamic response was taken up for the study. 
 The study group consisted of two groups who received two 
different doses of dexmedetomedine premedication and a control group which 
received normal saline as premedication. The  study subjects totalled 60, and 
each group had 20 subjects. 
DOSE OF DEXMEDETOMIDINE EMPLOYED AND ADMINISTERED 
 Various authors have employed different doses of 
dexmedetomidine for attenuation of sympathetic response and rise in intraocular 
pressure during laryngoscopy and intubation. Jakkola et al in 1992 used 0.6 
μg/kg body wight over 1 minute, before induction. Virkkila et al in 1994 used 
1μg/kg  intramuscularly    45 minutes before periocular block. Selcuk et al in 
2005 studied the effects of dexmedetomidine 1 μg/kg/hr I/V before periocular 
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block followed by 0.2 μg/kg/hr I/V infusion. Lee et al in 2007 employed 2.5 
μg/kg/hr I/V over 10 minutes before periocular block followed by 0.4 μg/kg/hr 
I/V infusion. Mowafi et al in 2008 used 0.6 μg/kg in 50 ml normal saline I/V 10 
minutes  before induction. Pal C K et al in 2011 used two doses 0.4 μg/kg and 
0.6 μg/kg in 10 ml saline I/V before induction. Xulili et al in 2012 studied with 
a dose of 0.5 μg/kg body weight 10 minutes before induction. Since most of the 
authors found that a dose of 0.4 μg/kg – 0.6 μg/kg was effective in attenauting 
the increase in IOP, a comparison of two doses of dexmedetomidine 0.4 μg/kg 
and 0.6 μg/kg was done in this study to determine a better dose in attenuating 
the hemodynamic response and rise in intraocular pressure with lesser side 
effects.  
METHOD OF ADMINISTRATION 
  In the present study , dexmedetomidine was prepared by 
adding 100 μg to a 50 ml normal saline to a concentration of 2 μg/ml and the 
required dose is given over 10 minutes. Administration of dexmedetomidine 
bolus rapidly will cause a transient increase in blood pressure and a reflex 
decrease in heart rate. This effect due to peripheral alpha 2 receptor stimulation 
in vascular smooth muscle can be avoided by  a slow infusion. Hence in this 
study administration of the drug  over 10 minutes  was used. This method of 
administration was similar to that used by Mowafi et al in their study. 
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TIMING OF ADMINISTRATION 
  From the proven pharmacokinetics of dexmedetomidine it is 
understood that rapid distribution half life of intravenous dexmedetomidine is 
approximately 6 minutes. Various authors have employed the dexmedetomidine 
administration 10 minutes before induction.  
  In view of the pharmacokinetic profile of the drug,in this  
study dexmedetomidne premedication was given 10 minutes before induction to 
attenuate the hemodynamic effects and rise in intraocular pressure of after 
succinyl choline, laryngoscopy and intubation. 
COMPARISON OF CASES AND CONTROL 
Change in IOP 
  Both groups were comparable in age, sex, weght , height, 
BMI, duration of surgery and ASA physical status and there was no statistically 
significant deifference between the groups.  
  The mean baseline intra ocular pressure in the control group 
was 16.5 ± 0.8 mmHg, of D4 group was 16.7 ± 0.4 mmHg and that of D6 was 
16.4 ± 0.8 mmHg. The baseline intraocular pressure was comparable among all 
three groups. The mean intraocular pressure after normal saline premedication 
in the control group was 16.5 ± 0.8 mmHg which did not show any change 
from the baseline value. However the mean intraocular pressure after 
95 
 
dexmedetomidine premedication in both the study groups were reduced; the 
mean IOP of  14.4 ± 0.6 mmHg in D4 and 14.0 ± 0.1 mmHg in D6. The 
reduction in intraocular pressure was statistically significant with a p value of 
<0.0001.After thiopentone administration the mean intraocular pressure reduced 
to a mean value of 15.1± 0.6 mmHg in control group which showed a reduction 
of 1.4 mmHg from the baseline value. The mean intraocular pressure decreased 
to a mean value of 13.8 ± 0.1mmHg in D4 group and a value of 12.6 ± 0.7 
mmHg in D6 group. There was statisticaly significant difference in intraocular 
pressure between the control and study groups.  The mean IOP after 
succinylcholine raised to a value of 19.3 ± 1.2 mmHg. The mean intraocular 
pressure of both the study groups also increased after succinyl choline 
administration; 15.7 ±  0.6 and 15.5 ± 0.7 in D4 and D6 groups respectively 
but the values never increased beyond the baseline value. The increase in IOP in 
control group was statistically significant when compared to both study groups , 
but a comparison  between D4 and D6 groups showed no statistical 
significance. There was a statistically significant rise of 4.1 mmHg after 
intubation to a mean intraocular pressure value of 20.6 mmHg in control group. 
The mean IOP in D4 and D6 groups also increased to 16.4 ± 0.4  mmHg and 
15.97 ± 0.5 mmHg respectively but still remained below the baseline. Between 
groups D4 and D6, showed no statistically  significant difference even though 
the reduction in intraocular pressure was more in  D6 group. The rise in 
intraocular pressure produced due to succinyl choline, laryngoscopy and 
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intubation persisted even upto 5 minutes after intubation and never returned to 
baseline. The mean IOP between control and study groups remained statistically 
significant even at 5 minutes after intubation. 
  The changes in intraocular pressure between the control and 
study groups corelated with the studies done by Mowafi et al . Pal C K et al also 
noted a similar trend in intraocular pressure after dexmedetomidine 
administration. Jakkola et al found a 34 % reduction in IOP after a 
dexmedetomidine bolus dose premedication  and this study observed a 12.1 % 
reduction in D4 group and 14.6 % reduction in D6 group. Ayoglu et al noted a 
decrease of 3.8 mm Hg from baseline intraocular pressure after 
dexmedetomidine bolus which almost corelates with our study . 
  Maximum reduction in intraocular pressure was noted in the 
study group after thiopentone administration which was 20.1 % and 23.1 % in 
D4 and D6 groups respectively. Various authors have studied the maximum 
reduction in IOP after dexmedetomidine administration. Seluck et al noted a 
maximum reduction of 28 % after a dexmedetomidine infusion of 0.2 μg/kg/hr. 
Change in pulse rate. 
  The mean baseline heart rate in the control and study groups 
were comparable. In the control group there was not much variation in heart rate 
after saline premedication. Whereas in both study groups there was a 
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statistically significant decrease in heart rate after dexmedetomidine 
premedication compared to baseline. The reduction in heart rate was more with 
D6 group which was statistically significant when compared to D4 group. There 
was statistically significant icrease in heart rate at various intervals in control 
group following intubation with a maximum increase immediately after 
intubation. Similar findings were observed in the studies of Aho et al. In the 
study groups also, the heart rate  increased after intubation but the initial 
dercrease in heart rate due to dexmedetomidine premedication blunted the 
sympathetic response  to a significant extent  so that the comparison between 
the study groups and control groups at various intervals upto 10 minutes after 
intubation showed statistically significant increase in heart rate in the control 
group at all time intervals. 
  Various authors have commented on the reduction in heart 
rate produced by dexmedetomidine . Mowafi et al noted a decrease of 14 beats 
after dexmedetomidine administration. Scheinin and Ferdi et al noted a decrease 
of 10 beats. Our study showed a significant reduction of 12 beats in D4 and a 
reduction of 15 beats in D6 group which correlates with these  previous studies.  
  Basar et al found that laryngoscopy and intubation produced 
a significant elevation of 10 beats from the baseline in control group and in 
dexmedetomidine group though the heart rate increased it was still less than 
baseline by 8 beats. This did not correlate with our study since, though the 
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increase in heart rate was attenuated by dexmedetomidine in the study groups 
the mean heart rate after intubation was above the baseline in both D4 and D6 
groups. But Aho et al found a similar increase in heart rate from the baseline in 
dexmedetomidine group. 
Changes in the systolic blood pressure 
  The baseline systolic blood pressure among study groups 
and control group was comparable. Immediately after intubation there was a 
highly significant rise in systolic blood pressure above the baseline  (16 mmHg) 
and it remained elevated above the baseline till 15 minutes after intubation.  
  Following dexmedetomidine premedication there was a 
decrease in systolic blood pressure in both the study groups which was 
statistically significant when compared to the control group. The fall in systolic 
B.P was more with D6 group which was statistically significant when compared 
to D4 group. Immediately after intubation though the systolic blood pressure in 
the study groups increased from the induction level the rise in systolic B.P was 
less when compared to control group and this was statistically highly significant 
also. The systolic blood pressure between D4 and D6 groups though showed a 
lesser mean value with D6 group after intubation ;it was not statistically 
significant. 
  Aho et al noted a similar finding of an increase of 40 mmHg  
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blood pressure  rise in control group and 18 mmHg rise in the dexmedetomidine 
group after intubation which was statistically significant. This compares with 
our study. 
  Scheinn et al observed an increase in systolic B.P of 18 mm 
Hg in control group immediately following intubation but the systolic B.P was 
less than the baseline after intubation in dexmedetomidine group. 
Changes in diastolic blood pressure 
  The baseline diastolic blood pressure was comparable in all 
three groups. There was a decrease in diastolic B.P after premedication in both 
the groups which was statistically significant when compared to control group. 
The decrease in B.P was more with D6 group which was also statistically 
significant. Aho et al, Kenya et al and Kunisawa et al also found similar 
decrease in diastolic blood pressure which concurs with our study. 
  In the control group there was a statistically significant 
increase in diastolic B.P immediately after intubation (a rise of 21 mmHg) when 
compared to the study groups. The mean diatolic B.P in D4 group slightly 
increased above the baseline following intubation,where as in D6 group  though 
the  mean diastolic B.P increased from the induction values after intubation it 
remained below the baseline . 
  Jakkola et al observed a significantly increased  diastolic  
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B.P(increase of 16 mmHg) in control group and a reduced diastolic B.P in 
dexmedetomidine group compared to baseline following intubation. This 
correlates with group D6 in our group and not with D4 group. 
Spo2 
  The baseline SPO2 ,SPO2 after premedication, after 
thiopentone, after succinylcholine ,after intubation  and during the surgery were 
comparable in all three groups. 
Side effects 
  one patient from the study group D4,  and  2 patients of D6 
group developed bradycardia who were managed by I/V atropine bolus dose. 5  
patients developed hypotension ; 1 from the control group , 2 from D4 and 2 
from D6 group which was managed by I/V fluids and intravenous ephedrine 
bolus.  
  3 patients 1 each from the control, D4 and D6 groups 
developed post operative dry mouth , 2 patients 1 from control and 1 from D6 
developed post operative shivering. 
  However the incidence of complications among all the three 
groups were statistically insignificant. 
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SUMMARY 
  A prospective randomized controlled study entitled “changes 
in intra ocular pressure following succinylcholine administration and 
endotracheal intubation – influence of dexmedetomidine ” was undertaken in 
Government Rajaji hospital attached to Madurai Medical College from after 
getting the institutional ethical committee clearance. 
  60 adult patients of 18- 60 years age group, ASA 1/2 
undergoing elective non ophthalmic surgeries under G.A were included in the 
study. The study population were randomly divided into three groups ; control 
,group D4 and Group D6.  
Control group- received normal saline as I/V premedication 10 minutes before 
induction. 
Group D4 – received 0.4 μg/kg I/V dexmedetomidine as premedication over 10 
minutes ,10 minutes before induction. 
Group D 6- received 0.6 μg/kg I/V  dexmedetomidine premedication over 10 
minutes , 10 minutes before induction. 
  After attaching all the standard monitors, patients were 
preoxygenated with 100 % oxygen for 3 minutes. The patients were induced 
with injection thiopentone 5 mg/kg, injection succinyl choline 1.5 mg/kg. After 
cessation of fasciculation orotracheal intubation was done with appropriate 
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sized cuffed endotracheal tube. The intraocular pressure, systolic B.P , diastolic 
B.P, SPO2 were recorded before premedication, 5 minutes after premedication, 
30 seconds after thiopentone , 30 seconds after succinyl choline, 1 minute and 5 
minutes after intubation. The hemodynamic parameters were also measured at 
various time intervals after intubation till the end of the procedure. 
The following table shows the results obtained in the present study: 
 CONTROL D4 D6 
Mean age in years 38.2 39.5 40.3 
Sex ratio;M:F 10:10 10:9 9:10 
Mean weight in Kg 53.3 54.3 53.5 
Mean height in cm 158.4 158.0 158.4 
Mean baseline IOP in mmhg 16.5 16.4 16.4 
Mean IOP 10 minutes after study drug(mmHg) 16.5 14.4 14.0 
Mean IOP 30 s after thiopentone (mmHg) 15.1 13.1 12.6 
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Mean IOP 30 s after succinycholine(mmHg) 19.3 15.7 15.5 
Mean IOP 1 minute after intubation (mmHg) 20.6 16.0 15.97 
Mean IOP 5 minutes after intubation( mmHg) 18.7 15.4 15.1 
Mean baseline heart rate(beats per minute) 83.2 82.6 82.4 
Mean heart rate after premedication (bpm) 83.2 70.3 67.6 
Mean heart rate immediately after 
intubation(bpm) 
118.00 101.00 100.30 
Mean baseline systolic B.P(mmHg) 125.10 125.00 125.50 
Mean systolic B.P after premedication(mmHg) 125.70 117.6 105.90 
Mean systolic B.P immediately after intubation 
(mmHg) 
141.3 131.8 130.0 
Mean baseline diastolic B.P(mmHg) 83.50 83.80 83.50 
Mean diastolic B.P after premedication 
(mmHg) 
83.60 73.8 69.0 
Mean diastolic B.P immediately after 
intubation (mmHg) 
104.70 84.90 82.60 
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   There was a significant reduction in IOP after 
premedication in both the study groups  which decreased further after 
thiopentone administration. After succinylcholine the IOP increased in both the 
groups D4 and D6 but it remained below the baseline and remained so even at 
5th minute after intubation which was statistically highly significant when 
compared to control group. Whereas in the control group the intraocular 
pressure  increased significantly after succinylcholine and intubation and 
remained elevated above baseline even at 5 th minute of intubation. But though 
the mean intraocular pressure after succiylcholine and intubation was lesser in 
D6 group it was not statistically significant which shows that both doses are 
equally efficacious in blunting the rise of IOP after succinylcholine and 
intubation. 
  There was a significant decrease in heart rate after 
premedication in both study groups when compared to control group. Heart rate 
increased markedly after succinylcholine and intubation in the control group 
whereas in both study groups, the increase in heart rate due to laryngoscopy and 
intubation was attenuated by the dexmedetomidine premedication. Another 
important finding was that the reduction in heart rate was more after 
premedication in group D6  and this was found statistically significant when 
compared to D4 group. But at the same time there was no statistical significance 
between the mean heart rate after intubation between the two groups D4 and D6 
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which  implied the degree of attenuation of sympathetic response by the two 
doses of dexmedetomidine was similar. 
  Similar to changes in heart rate, the reduction in systolic and 
diastolic B.P after premedication in both the study groups was also statistically 
significant when compared to control group. And between groups D4 and D6 
the reduction in systolic and diastolic B.P was more in group D6 which was also 
statistically significant. The  mean systolic and diastolic B.P after intubation 
was significantly less than the control group indicating the efficacy of 
dexmedetomidine in attenuating the sympathetic response. However a 
comparison of the mean systolic and diastolic B.P after intubation between the 
two groups D4 and D6 showed that the values between the two groups did not 
differ significantly which implies the degree of attenuation of sympathetic 
response by the two doses of dexmedetomidine was comparable. 
  There were a few complications like hypotension in 2 
patients of D4 and 2 patients of D6 group, and bradycardia 1 case of D4 group 
and 2 cases of D6 group. 
  Thus both the doses of dexmedetomidine were equally 
effective in preventing the rise of intra ocular pressure  associated 
withsuccinylcholine administration, laryngoscopy and intubation. However the 
degree of reduction in heart rate ,systolic B.P and diastolic B.P after 
premedication with dexmedetomidine was more  with the dose of  0.6 μg/kg I/V 
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and so is the case with the incidence of the minimal side effects which occurred. 
At the same time the degree of attenuation of sympathetic response during 
laryngoscopy and intubation was comparable between both the doses of 
dexmedetomidine as is evidenced by the statistically insignificant difference 
between the heart rate and blood pressure follwing intubation among both the 
study groups.  Hence a better hemodynamic stability was achieved with the 
dose of 0.4 μg/kg/I/V at the same time with a significant reduction in IOP. 
     The direct vasoconstrictor effect of dexmedetomidine on the 
afferent blood vessels of  ciliary body  leads to the decreased aqueous humour 
production. It also reduces the sympathetically mediated tone of ocular drainage 
system and thus facilitates the drainage of aqueous humour. The hemodynamic 
effects of dexmedetomidine may also be responsible for the intraocular pressure 
lowering effect. 
  Hence though both the doses of dexmedetomidine may be 
suggested for attenuation of rise of IOP and sympathetic response ,and a more 
desirable dose is 0.4 μg/kg/I/V  in terms of hemodynamic stability. 
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CONCLUSION 
  Dexmedetomidine premedication at doses 0.4 μg/kg I/V and 
0.6 μg/kg I/V diluted in normal saline at a 2μg/ml concentration administered 
over 10 minutes as premedication 10 minutes before induction were both 
equally effective in significant obtundation of the rise in intraocular pressure 
associated with succinyl choline administration and intubation. It also 
attenuated significantly the sympathetic  response to laryngoscopy and 
intubation.  But a more desirable hemodynamic stability was achieved with the 
dose 0.4 μg/kg I/V.    Therefore dexmedetomidine  0.4 μg/kg I/V 
premedication can be used for attenuating the rise in intraocular pressure 
associated with succinyl choline administration and intubation in situations 
where rise of intraocular pressure may be detrimental.  
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LIST OF ABBREVIATIONS 
BMI     : body mass index 
SBP     : systolic blood pressure 
DBP     : diastolic blood pressure 
HR     : heart rate 
IOP     :intra ocular pressure 
ASA     :American Society of Anaesthesiologist 
g     :gram 
IV     :intravenous 
IM     :intra muscular 
Kg     :kilogram 
L     :litre 
SD     :standard deviation 
Mcg     :microgram 
MIN     : minute 
ML     : millilitre 
BT     : bleeding time 
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CT     :clotting time 
ECG     :electro cardio graph 
BPM     :beats per minute 
GABA     : gama amino butyric acid 
INJ     :injection 
LMA     :laryngeal mask airway 
mmHg     :millimeter mercury 
α1     :alpha 1 
α2     :alpha 2 
%     :percentage 
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PROFORMA 
NAME     :                                                            
 I.P.NO     :                 
AGE & SEX    :                                                                
 ASA      :                                                                          
WEIGHT              :  
HEIGHT         : 
DATE& TIME  OF ADMISSION   :                                             
DATE& TIME OF  DISCHARGE    : 
DIAGNOSIS      :  
PROPOSED SURGERY    : 
PROCEDURE     : 
HISTORY       : 
 HYPERTENSION 
 OTHER SYSTEMIC ILLNESS 
 ACUTE OR CHRONIC EYE DISEASE 
 DRUG THERAPY 
  ALLERGY TO DRUGS 
CLINICAL EXAMINATION :  
 PULSE RATE 
 BLOOD PRESSURE 
 SPO2 
 PALLOR,ICTERUS,CLUBBING,CYANOSIS,LYMPHADENOPATHY
,  EDEMA 
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 CARDIOVASCULAR SYSTEM 
 RESPIRATORY SYSTEM 
 ORAL CAVITY  
 AIRWAY 
 NECK & SPINE 
BASIC INVESTIGATIONS:- 
      HAEMOGLOBIN 
      RENAL PARAMETERS & SERUM  ELECTROLYTES, 
      ECG   
      CHEST X RAY PA VIEW 
  BT, CT 
      RBS 
ASA I/II 
 
 
 
IOP GROUP 
CONTROL 
GROUP 
D4 
GROUP 
D6 
BEFORE 
PREMEDICATION(BASELINE) 
   
5 MINUTES AFTER 
PREMEDICATION 
   
30 SECONDS AFTER 
THIOPENTONE INDUCTION  
   
30 SECONDS AFTER 
SUCCCINYL CHOLINE 
   
1MIN AFTER INTUBATION    
5 MINUTES AFTER 
INTUBATION                        
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 Baseline 
Before 
premedic
ation 
 5 
MINUT
ES 
After 
pre 
medicat
ion 
30 s 
After 
inducti
on 
30 s After 
succinyl 
choline 
 1 
MINU
TE 
After 
intubati
on  
5 MIN 10 
min 
15  
min 
Pulse 
rate 
        
Systol
ic B.P 
        
Diasto
lic 
B.P 
        
spO2         
 
 
COMPLICATIONS IF ANY: 
DURATION OF SURGERY 
 
 30 min 45 
min 
60 
min 
75 
min 
90 
min 
105 
min 
120 
min 
PR        
SBP        
DBP        
spO₂        
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PLAGIARISM CERTIFICATE 
 
 
 
D6
SL.NO NAME AGE SEX WEIGHT HEIGHT
AS
A
DURATIO
N OF 
SURGERY
IOP 
BASELINE
IOP AFTER 
PREMEDIC
ATION
IOP 
AFTER 
THIOPE
NTONE
IOP 
AFTER 
SUCINYL 
CHOLINE
IOP 1 
MIN 
AFTER 
INTUBA
TION
IOP 5 
MIN 
AFTER 
INTUBA
TION
PUSE 
RATE 
BASELINE
AFTER 
PREMEDIC
ATION
AFTER 
THIOPE
NTONE
AFTER 
SUCCINYL 
CHOLINE
1 MIN 
AFTER 
INTUBA
TION
5 MIN 10 MIN 15 MIN 30 MIN 45MIN
1 MAHALINGAM 39 M 55 155 1 120 MIN 15.9 13.4 12.2 15.9 16.5 15.9 80 70 70 72 100 98 80 84 80 86
2 MUTHUMARI 29 F 60 160 1 90 MIN 16.5 13.4 12.6 15.9 15.9 14.6 82 72 74 74 98 90 82 80 82 80
3 ILAKKIYA 45 F 56 157 2 60 MIN 17.3 14.6 12.2 15.1 16.5 15.9 84 68 68 70 104 100 84 90 84 82
4 RAMAR 49 M 49 165 2 90 MIN 15.9 12.2 11.2 14.6 16.5 15.5 86 64 64 64 100 98 86 80 86 78
5 PALANI 55 M 49 167 1 120 MIN 16.5 13.4 12.2 15.1 15.9 15.1 84 62 62 62 102 96 84 78 84 90
6 CHINNAMMAL 38 F 50 159 2 90 MIN 17.3 14.6 13.4 15.9 15.9 14.6 82 68 68 68 104 100 82 82 82 82
7 SURESH 48 M 60 160 1 120 MIN 15.9 13.4 12.2 15.9 16.5 15.5 80 70 78 78 98 98 80 80 86 80
8 MEENA 39 F 49 163 2 60 MIN 17.3 15.1 13.4 15.9 15.5 14.6 78 66 66 66 106 106 70 78 78 90
9 SELVAM 29 M 56 158 1 120 MIN 15.9 13.4 12.6 15.9 16.5 15.5 80 64 64 64 98 98 80 90 80 84
10 KUMARI 28 F 60 157 1 60 MIN 17.3 15.9 13.4 16.5 15.9 15.5 84 78 78 78 100 100 84 80 84 90
11 SELVI 24 F 65 155 2 60 MIN 17.3 13.4 12.2 15.9 15.1 14.6 82 62 66 68 92 90 82 78 82 80
12 BALAMURUGAN 53 M 48 159 2 75MIN 16.5 15.1 13.4 15.9 15.5 15.1 88 70 70 74 100 96 88 90 88 88
13 MUTHU 51 M 53 157 1 120 MIN 16.5 13.4 12.2 15.1 15.9 15.5 78 64 64 64 102 102 78 86 78 74
14 RAKKAMMAL 49 F 53 158 1 90 MIN 14.6 13.4 12.6 13.9 15.9 13.9 80 70 70 70 101 100 80 78 80 80
15 PANJU 52 F 52 154 2 75MIN 17.3 14.6 13.4 15.9 15.9 15.1 84 64 64 64 102 102 84 84 84 78
16 MANISAMY 44 M 50 155 2 60 MIN 14.6 14.6 13.4 16.5 15.1 15.1 82 66 66 66 100 98 82 82 80 82
17 RAKKU 38 F 54 156 1 120 MIN 15.9 12.2 11.2 14.6 15.5 14.1 88 74 74 74 98 98 88 88 70 88
18 KALI 39 M 46 154 2 90 MIN 16.5 15.1 12.2 15.1 16.5 15.9 86 62 62 68 98 94 86 86 88 86
19 SUSEELA 35 F 55 159 1 75MIN 17.3 14.6 13.4 16.5 15.9 15.9 80 72 74 74 100 100 80 80 86 80
20 RAVI 22 M 50 160 2 120 MIN 16.5 13.4 12.2 14.6 16.5 14.6 80 66 66 66 102 102 80 86 80 80
D6
60 MIN 75 MIN 90 MIN
105 
MIN
120 
MIN
SYSTOLI
C BP 
BASELIN
E
AFTER 
PREME
D
AFTER 
THIOPE
NTONE
AFTER 
SUCCIN
YL 
CHOLIN
E
1 MIN 
AFTER 
INTUBA
TION
5  MIN 
AFTER 
INTUBA
TION
10MIN 15 MIN 30 MIN 45 MIN 60 MIN 75 MIN 90 MIN
105 
MIN
120 
MIN
DIASTOLI
C 
BASELINE
D.BP 
AFTER 
PREMED
D.BP 
AFTER 
THIOPE
NTONE
D.BP 
AFTER 
SUCCIN
YLCHOLI
NE
DIASTO
LIC 
1MIN 
AFTER 
INTUBA
TION
5 MIN
80 78 80 90 80 120 110 112 120 130 126 120 130 150 148 148 140 136 140 130 82 70 70 74 78 76
82 78 82 88 82 130 114 116 120 128 128 130 136 128 136 128 136 128 136 128 88 72 70 72 80 78
84 78 84 80 84 110 108 110 120 128 128 110 129 128 140 120 130 118 130 120 84 72 72 72 78 78
86 90 86 86 86 124 100 106 108 126 126 124 128 130 130 126 140 130 140 126 90 74 72 74 80 80
84 70 84 84 84 132 102 104 112 130 128 132 120 140 128 128 116 136 116 128 78 70 70 80 80 80
84 82 82 82 82 140 110 116 118 124 124 140 123 140 130 126 130 128 130 126 84 64 64 64 84 80
80 90 80 78 80 122 106 106 110 130 130 122 124 100 128 136 98 134 98 136 70 60 60 60 70 70
78 78 78 84 78 128 112 114 120 130 130 128 130 108 116 130 140 130 130 130 92 68 68 68 80 80
80 80 70 80 80 118 100 108 114 128 128 118 135 130 140 122 130 118 130 122 80 70 68 70 80 80
84 84 78 84 84 130 102 106 120 134 130 130 130 136 128 128 120 128 120 128 80 72 72 72 78 78
82 82 82 90 82 128 106 108 100 128 128 128 132 130 130 110 128 130 128 110 70 66 66 70 76 76
76 88 70 98 88 124 110 118 116 130 110 124 130 140 108 136 130 130 130 136 80 70 70 70 80 80
78 76 78 78 78 122 102 102 110 128 128 122 128 100 140 128 98 120 98 128 90 68 68 68 90 88
82 80 84 74 80 130 98 100 110 140 140 130 130 130 136 134 120 136 120 134 90 70 68 80 78 78
84 84 80 84 92 112 106 108 110 130 130 112 128 110 130 130 130 128 130 130 100 70 70 70 98 90
76 82 82 82 90 120 110 118 120 140 110 120 126 140 128 128 140 130 140 128 70 68 68 70 80 80
80 88 90 76 88 130 102 102 108 124 124 130 128 130 140 110 98 130 98 110 70 72 70 72 80 80
84 86 80 88 86 134 98 100 126 130 130 134 120 130 132 128 136 140 136 128 92 70 70 70 92 92
82 80 84 80 78 136 112 112 114 132 120 136 124 140 128 146 130 130 130 146 80 64 68 64 90 90
78 80 82 80 90 120 110 110 114 130 130 120 130 138 134 132 130 128 130 132 100 70 70 70 100 100
D6
10 MIN 15 MIN 30 MIN 45 MIN 60 MIN 75 MIN 90 MIN
105 
MIN
120 
MIN
SPO2 
BASELINE
AFTER 
PREMEDIC
ATION
AFTER 
THIOPENT
ONE
AFTER 
SUCCINYLCHO
LINE
1 MIN AFTER 
INTUBATION
5 MIN 10 MIN 15 MIN 30 MIN 45 MIN 60MIN 75MIN 90MIN
105MIN
120MIN
120 
MIN
70 76 68 80 80 84 80 78 84 98 98 98 98 98 98 98 98 98 98 98 98 98 98 98
80 80 84 68 84 80 70 100 80 99 99 99 99 99 99 99 99 99 99 99 99 99 99 99
90 78 70 90 80 74 90 70 74 98 98 98 98 98 98 98 98 98 98 98 98 98 98 98
78 88 90 88 78 90 88 88 90 99 99 99 99 99 99 99 99 99 99 99 99 99 99 99
76 90 70 84 88 78 84 80 78 98 98 98 98 98 98 98 98 98 98 98 98 98 98 98
82 74 88 90 96 90 90 96 90 99 99 99 99 99 99 99 99 99 99 99 99 99 99 99
80 90 80 80 100 88 84 78 88 98 98 98 98 98 98 98 98 98 98 98 98 98 98 98
78 68 100 80 84 90 80 80 90 98 98 98 98 98 98 98 98 98 98 98 98 98 98 98
70 80 70 74 80 70 70 70 70 98 98 98 98 98 98 98 98 98 98 98 98 98 98 98
78 70 80 70 70 88 70 80 88 99 99 99 99 99 99 99 99 99 99 99 99 99 99 99
76 88 88 84 84 88 84 74 88 99 99 99 99 99 99 99 99 99 99 99 99 99 99 99
78 74 88 74 80 84 74 84 84 98 98 98 98 98 98 98 98 98 98 98 98 98 98 98
88 100 84 80 74 84 80 100 84 99 99 99 99 99 99 99 99 99 99 99 99 99 99 99
78 78 78 84 90 78 84 90 78 97 97 97 97 97 97 97 97 97 97 97 97 97 97 97
90 90 96 88 78 84 100 96 84 98 98 98 98 98 98 98 98 98 98 98 98 98 98 98
80 78 74 90 84 100 90 90 100 99 99 99 99 99 99 99 99 99 99 99 99 99 99 99
80 90 80 84 100 70 84 78 70 97 97 97 97 97 97 97 97 97 97 97 97 97 97 97
92 84 88 84 84 90 88 84 90 97 97 97 97 97 97 97 97 97 97 97 97 97 97 97
90 90 70 78 80 84 78 100 84 98 98 98 98 98 98 98 98 98 98 98 98 98 98 98
100 70 80 100 90 70 100 80 70 99 99 99 99 99 99 99 99 99 99 99 99 99 99 99
CONTROL CHART
SL.NO NAME AGE SEX WEIGHT HEIGHT ASA
DURATION 
OF 
SURGERY
IOP 
BASELINE
I0P 
AFTER 
PREMED
ICATION
IOP 
AFTER 
THIOPE
NTONE
IOP AFTER 
SUCCINYL 
CHOLINE
IOP 1 
MIN 
AFTER 
INTUBA
TION
IOP 5  
MIN 
AFTER 
INTUBA
TION
PULSE 
RATE 
BASELINE
PULSE 
RATE 
AFTER 
PREMED
ICATION
PULSE 
RATE 
AFTER 
THIOPE
NTONE
AFTER 
SUCCINYL 
CHOLINE
1 MIN 
AFTER 
INTUBA
TION
5 MIN 
AFTER 
INTUBA
TION
10 MIN 15 MIN 30 MIN
1 RAMALINGAM 45 M 60 155 1 120 17.3 17.3 15.6 20.6 20.1 18.9 82 84 84 86 100 100 98 82 82
2 RAMA 34 F 55 160 1 90 15.9 15.9 14.6 18.9 21.9 16.5 84 82 84 84 120 104 100 84 84
3 VELAMMAL 27 F 50 154 1 60 14.6 14.6 14.3 20.1 21.9 18.9 80 80 86 86 126 98 96 80 80
4 CHELLAMMA 42 F 65 163 2 120 15.6 15.6 14.6 20.1 20.1 18.9 78 78 78 82 130 106 104 78 78
5 SEETHAMMAL 55 F 48 160 2 90 17 17 15.9 18.5 20.6 18.9 86 88 88 88 116 110 100 86 86
6 DEVAKUMAR 29 M 55 158 1 60 16.5 16.5 15.6 19.6 20.1 17.3 88 86 86 88 118 98 90 90 90
7 VETRIVELSELVI 34 F 50 164 2 120 15.9 15.9 14.3 17.3 18.9 17.3 84 84 84 84 122 104 88 86 86
8 RAMARANI 24 F 60 160 1 75 17.3 17.3 15.6 20.1 21.9 18.9 82 82 82 82 106 106 80 82 84
9 SELVI 41 F 50 160 2 90 16.5 16.5 15.9 18.9 20.1 17.3 86 86 88 88 132 98 90 86 90
10 MEENACHI 48 F 55 155 1 60 17.3 17.3 15.6 18.5 20.6 18.9 84 84 84 84 128 98 93 84 84
11  AYYAVO 39 M 60 159 2 75 15.6 15.6 14.6 18.5 20.1 19.6 86 86 86 90 130 104 100 86 86
12  SELVARAJ 42 M 64 161 2 120 15.9 15.9 14.3 17.3 18.9 18.5 82 82 84 84 116 106 88 82 82
13 MUTHUMARI 38 F 54 164 2 90 17.3 17.3 14.6 22.4 21.9 20.1 88 88 88 90 126 110 78 88 88
14 MUTHUKUMAR 44 M 50 150 1 60 16.5 16.5 15.6 20.1 21.9 19.6 78 86 86 86 116 98 86 80 80
15  PAULSAMY 29 M 55 153 1 120 17.3 17.3 15.9 20.6 20.6 19.6 86 78 78 78 118 110 72 86 88
16 MOHAN 32 M 52 158 2 75 15.6 15.6 14.6 18.5 20.6 18.5 82 82 86 88 100 106 68 82 82
17 BALAMURUGAN 52 M 50 162 2 90 15.9 15.9 14.3 18.5 18.9 18.5 86 86 86 86 126 104 90 86 86
18 FATHIMA 37 F 45 156 1 75 17.3 17.3 15.6 20.6 21.9 20.6 78 82 82 84 116 100 88 78 78
19 MUTHU 48 M 47 160 1 120 16.5 16.5 15.6 18.9 20.1 18.5 82 78 80 84 114 104 80 82 82
20 MAYAPPAN 24 M 40 155 2 120 17.3 17.3 14.6 18.5 20.9 18.5 82 82 82 82 100 110 86 82 82
1065 1830 329.1 386.5 412 373.8 1664 1664 1682 1704 2360 2074 1775 1670 1678
CONTROL CHART
45 MIN 60MIN 75 MIN 90MIN 105 MIN 120 MIN
SYSTOLI
C BP 
BASELIN
E
AFTER 
PREMED
AFTER 
THIOPE
NTONE
AFTER 
SUCCINY
L 
CHOLIN
E
1MIN 
AFTER 
INTUBA
TION
5 MIN 
AFTER 
INTUBA
TION
10 MIN 15 MIN 30 MIN 45 MIN 60 MIN 75 MIN 90 MIN 105 MIN 120 MIN
DIASTOLIC 
BASELINE
DIASTOL
IC AFTER 
PREMED
ICATION
D.BP 
AFTER 
THIOPE
NTONE
DIASTOLI
C AFTER 
SUCCINYL 
CHOLINE
D.BP 1 
MIN 
AFTER 
INTUBA
TION
82 82 82 82 82 82 120 120 118 120 138 130 128 130 140 138 140 132 136 120 130 80 80 78 80 100
84 84 84 92 122 122 120 122 138 138 138 136 130 136 128 136 112 70 72 72 72 110
80 80 80 80 80 80 124 124 116 124 134 130 140 129 128 140 120 130 118 130 120 86 86 86 86 100
78 78 74 78 78 70 126 128 108 130 138 134 136 128 130 130 122 140 130 140 122 90 90 80 90 100
86 86 86 86 78 86 120 120 114 120 136 138 130 120 140 128 128 112 136 112 122 80 80 80 80 98
70 90 90 100 90 90 122 122 122 122 140 132 140 123 136 130 126 130 128 130 126 82 82 82 82 110
86 86 86 86 86 86 130 134 126 134 152 130 138 124 100 120 124 98 134 98 136 70 70 70 70 116
82 78 82 82 82 82 132 130 128 130 140 140 128 130 108 116 130 140 125 130 130 100 98 98 98 108
86 86 86 86 86 86 128 128 118 128 138 130 126 135 130 140 122 130 118 130 122 90 90 90 90 100
84 84 84 84 84 80 120 122 116 122 138 136 148 130 136 128 128 12 124 122 130 80 80 80 80 98
78 80 86 86 86 86 124 126 120 136 143 138 130 132 120 130 112 128 130 128 112 70 70 68 68 104
82 82 82 98 68 82 122 120 118 120 144 138 136 130 140 108 136 130 112 130 136 80 78 78 78 114
88 88 88 88 72 88 130 132 128 132 148 140 134 128 100 128 128 98 122 100 128 100 100 100 100 116
80 80 90 80 80 80 128 130 126 130 144 136 130 130 130 136 124 120 136 120 134 90 88 88 88 108
86 86 86 86 86 86 128 128 120 128 140 138 132 128 110 130 130 130 128 130 124 80 80 72 80 100
82 82 82 82 82 82 120 122 118 134 142 138 138 126 140 132 128 140 130 140 128 80 80 80 80 108
86 86 86 86 86 86 124 124 120 124 142 136 136 128 122 118 116 98 130 98 110 70 72 72 72 100
78 78 78 78 78 78 126 126 120 126 140 140 137 120 130 132 128 132 130 112 128 92 92 92 92 98
82 82 82 82 82 82 120 124 118 124 140 138 130 124 140 128 146 130 140 120 130 80 84 84 84 96
82 82 82 82 82 82 136 132 130 132 150 140 144 130 138 134 132 130 128 130 132 100 100 100 100 110
1642 1660 1676 1704 1548 1574 2502 2514 2404 2538 2825 2720 2699 2561 2548 2582 2548 2396 2547 2320 2400 1670 1672 1650 1670 2094
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5 MIN 10 MIN 15 MIN 30 MIN 45 MIN 60 MIN 75 MIN 90 MIN 105MIN 120 MIN
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INTUBA
TION
5 MIN 10 MIN 15 MIN 30MIN 45 MIN 60 MIN 75 MIN 90 MIN 105 MIN 120 MIN
98 96 74 90 80 100 84 78 100 88 98 98 98 98 98 98 98 98 98 98 98 98 98 98 98
100 90 80 84 70 84 80 100 84 99 99 99 99 99 99 99 99 99 99 99 99 99 99 99
98 92 78 90 90 80 74 70 80 80 98 99 98 98 99 98 99 98 98 98 98 98 98 98 98
96 90 88 90 88 78 90 88 78 90 99 98 99 99 98 99 98 99 99 99 99 99 99 99 99
90 88 100 70 84 100 78 80 100 88 98 99 98 98 99 98 99 98 98 98 98 98 98 98 98
100 108 74 88 90 96 90 96 96 90 99 98 99 99 98 99 98 99 99 99 99 99 99 99 99
100 90 90 100 84 100 88 78 100 90 98 99 98 98 99 98 99 98 98 98 98 98 98 98 98
104 80 70 90 80 84 90 80 84 96 98 98 98 98 98 98 98 98 98 98 98 98 98 98 98
98 88 80 70 70 80 70 70 80 70 98 99 98 98 99 98 99 98 98 98 98 98 98 98 98
90 86 70 80 70 90 88 80 90 90 99 98 99 99 98 99 98 99 99 99 99 99 99 99 99
100 88 88 88 84 84 88 74 84 90 99 99 99 99 99 99 99 99 99 99 99 99 99 99 99
106 96 74 88 74 80 84 84 80 80 98 98 98 98 98 98 98 98 98 98 98 98 98 98 98
108 98 100 84 80 74 84 100 74 88 99 99 99 99 99 99 99 99 99 99 99 99 99 99 99
100 106 78 78 84 90 78 90 90 74 97 98 97 97 98 97 98 97 97 97 97 97 97 97 97
90 100 90 96 100 78 84 96 80 90 98 99 98 98 99 98 99 98 98 98 98 98 98 98 98
104 108 78 74 90 84 100 90 84 70 99 99 99 99 99 99 99 99 99 99 99 99 99 99 99
98 90 100 80 84 100 70 78 100 80 97 98 97 97 98 97 98 97 97 97 97 97 97 97 97
90 96 84 100 88 84 90 84 84 96 97 98 97 97 98 97 98 97 97 97 97 97 97 97 97
88 86 90 70 78 80 84 100 80 80 98 98 98 98 98 98 98 98 98 98 98 98 98 98 98
90 80 70 80 100 90 70 80 90 78 99 99 99 99 99 99 99 99 99 99 99 99 99 99 99
1948 1856 1656 1690 1668 1736 1664 1696 1738 1608
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15MIN
30 
MIN
1 PRABHA 40 M 55 159 2 120 17.3 14.6 13.4 16.5 16.5 15.9 82 72 72 74 98 90 82 84 82
2 MUTHUMARI 45 F 50 155 1 90 15.9 14.3 13.4 15.5 15.9 15.1 86 78 68 68 94 93 86 76 86
3 KALI 38 M 60 165 2 75 17.3 14.6 12.2 15.9 16.5 15.9 84 68 78 80 100 94 84 84 84
4 SUNDAR 49 M 58 153 1 90 14.6 13.4 12.2 16.5 16.5 15.9 78 68 68 68 98 100 78 80 78
5 SOUMYA 23 F 54 154 2 60 16.5 14.3 13.4 15.5 15.9 15.1 88 70 72 72 96 94 88 90 88
6 MARI 55 M 54 160 1 120 15.6 14.6 12.2 15.1 16.5 16.5 84 70 72 72 106 94 84 84 83
7 ANANDI 52 F 52 156 2 75 16.5 15.1 14.3 15.1 16.5 15.9 82 66 68 72 104 93 82 82 86
8 PETCHIMUTHU 49 M 50 164 2 120 15.9 14.6 13.4 15.5 15.5 14.3 86 78 74 74 98 90 86 90 86
9 KALA 39 F 56 157 1 60 17.3 15.1 14.3 16.5 16.5 15.9 88 70 70 70 100 98 88 78 88
10 MEENA 48 F 50 155 1 120 16.5 13.4 12.2 15.1 15.9 15.1 80 68 70 74 106 90 80 78 80
11 RAMAR 39 M 55 154 2 60 15.9 14.3 13.4 14.3 15.5 14.3 78 68 70 70 92 93 78 80 78
12 SURYA 23 M 45 162 2 75 16.5 14.6 12.2 15.9 15.5 14.3 82 66 66 70 106 94 82 82 82
13 VELU 52 M 60 153 1 90 15.9 13.4 12.2 15.9 15.9 15.1 78 74 72 72 108 102 78 78 80
14 SUSEELA 39 F 62 154 1 120 15.9 14.3 13.4 15.5 15.9 14.3 84 70 72 72 102 98 84 80 84
15 SHYAMALA 27 F 65 159 2 60 17.3 14.6 13.4 15.9 15.9 15.1 86 78 80 80 98 90 84 86 86
16 KALI 29 M 59 160 1 60 16.5 15.1 14.3 15.5 15.5 14.3 84 68 66 66 108 96 84 80 84
17 REMA 34 F 58 164 1 120 15.9 13.4 12.2 15.5 15.5 15.1 83 64 64 68 106 94 83 83 78
18 PREMA 29 F 45 161 2 90 17.3 15.1 13.4 16.5 16.5 16.5 80 70 68 68 100 90 80 84 80
19 MUTHU 42 M 48 155 1 120 16.5 14.6 12.2 15.5 15.9 15.9 78 68 68 68 94 94 78 78 78
20 KAVITHA 38 F 50 160 2 90 17.3 15.1 13.4 16.5 16.5 16.5 80 72 72 72 106 96 80 80 80
1086 1815 328 321 307
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D.BP 
AFTER 
SUCCI
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NE
82 86 82 88 82 82 124 120 114 124 130 128 128 130 150 148 148 140 136 140 130 70 70 70 70
88 86 86 90 86 88 120 116 116 116 128 120 120 124 128 136 128 136 128 136 128 80 72 68 72
84 84 84 80 84 84 122 122 122 122 128 120 118 129 128 140 120 130 118 130 120 86 80 78 80
74 78 76 78 70 78 126 116 116 116 126 122 130 130 130 130 126 140 130 140 126 90 80 78 80
86 88 84 88 90 88 120 112 112 112 130 128 130 120 140 128 128 116 136 116 128 80 70 68 70
84 90 84 78 84 90 126 114 114 118 124 120 130 123 140 130 126 130 128 130 126 82 80 80 84
90 82 80 82 78 82 138 124 124 124 138 132 118 124 100 128 136 98 134 98 136 70 60 60 60
86 78 86 80 80 86 100 122 118 122 130 128 120 130 108 116 130 140 130 130 130 90 80 72 80
92 88 80 88 84 88 122 114 102 118 128 126 120 135 130 140 122 130 118 130 122 88 70 68 70
84 80 86 80 78 88 126 122 122 122 134 130 128 118 136 128 128 120 128 120 128 80 72 72 72
76 78 94 80 76 78 128 100 98 100 138 128 116 132 130 130 110 128 130 128 110 70 68 68 70
80 82 82 88 82 88 124 118 118 116 130 120 118 118 140 108 136 130 130 130 136 80 70 70 70
78 78 90 78 88 78 126 114 114 114 128 128 128 128 100 140 128 98 120 98 128 100 90 80 90
83 88 84 84 84 78 130 122 120 120 140 138 116 130 130 136 134 120 136 120 134 78 70 68 70
80 86 78 86 78 86 124 114 114 114 136 130 128 124 110 130 130 130 128 130 130 100 80 70 88
84 80 84 88 84 90 140 136 118 136 140 128 130 126 140 128 128 140 130 140 128 80 70 68 70
83 83 90 83 70 83 124 114 114 114 136 136 120 122 130 140 110 98 130 98 110 80 72 72 72
80 78 80 82 80 88 126 120 120 132 130 128 106 120 130 132 128 136 140 136 128 92 80 70 80
78 84 78 80 78 78 124 112 112 112 132 132 116 124 140 128 146 130 130 130 146 80 72 72 76
84 80 88 80 72 80 130 120 120 120 130 130 116 130 138 134 132 130 128 130 132 100 70 70 70
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80 78 76 68 80 70 100 84 100 78 90 98 98 98 98 98 98 98 98 98 98 98 98 98 98 98
80 70 72 80 84 70 70 80 84 100 84 99 99 99 99 99 99 99 99 99 99 99 99 99 99 99
86 80 90 78 88 90 84 74 80 70 90 99 98 98 98 98 98 98 98 98 98 98 98 98 98 98
90 80 80 88 90 88 78 90 78 88 90 98 99 99 99 99 99 99 99 99 99 99 99 99 99 99
80 80 82 80 70 84 70 78 100 80 70 99 98 98 98 98 98 98 98 98 98 98 98 98 98 98
86 86 86 74 88 90 96 90 96 96 88 98 99 99 99 99 99 99 99 99 99 99 99 99 99 99
70 70 80 90 80 80 100 88 100 78 100 99 98 98 98 98 98 98 98 98 98 98 98 98 98 98
90 80 70 70 90 80 84 90 84 80 90 98 98 98 98 98 98 98 98 98 98 98 98 98 98 98
80 80 80 70 70 70 80 70 80 70 70 99 98 98 98 98 98 98 98 98 98 98 98 98 98 98
80 78 78 70 80 70 90 88 90 80 80 98 99 99 99 99 99 99 99 99 99 99 99 99 99 99
76 76 74 88 88 84 84 88 84 74 88 99 99 99 99 99 99 99 99 99 99 99 99 99 99 99
80 80 80 74 90 74 80 84 80 84 88 98 98 98 98 98 98 98 98 98 98 98 98 98 98 98
100 100 100 100 84 80 74 84 74 100 84 99 99 99 99 99 99 99 99 99 99 99 99 99 99 99
78 78 78 78 78 84 90 78 90 90 78 98 97 97 97 97 97 97 97 97 97 97 97 97 97 97
100 90 90 90 96 88 78 84 78 96 96 99 98 98 98 98 98 98 98 98 98 98 98 98 98 98
80 80 80 78 74 90 84 100 84 90 74 99 99 99 99 99 99 99 99 99 99 99 99 99 99 99
80 80 80 90 80 84 98 70 100 78 80 98 97 97 97 97 97 97 97 97 97 97 97 97 97 97
92 92 92 84 100 88 84 90 84 84 100 98 97 97 97 97 97 97 97 97 97 97 97 97 97 97
90 88 88 90 70 78 80 84 80 100 70 98 98 98 98 98 98 98 98 98 98 98 98 98 98 98
100 100 100 70 80 100 90 70 90 80 80 99 99 99 99 99 99 99 99 99 99 99 99 99 99 99
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